

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16432 A2

(51) International Patent Classification⁷: **C07K 14/705**,
16/28, C12N 15/12, 15/11

(21) International Application Number: **PCT/DK01/00550**

(22) International Filing Date: **20 August 2001 (20.08.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
PA 2000 01259 25 August 2000 (25.08.2000) DK

(71) Applicants: **NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).**

(72) Inventors: **WAHL, Philip; Ved Andebakken 8, 4th, DK-2000 Frederiksberg (DK). VISSING, Henrik; Virumstræde 13A, DK-2830 Virum (DK). GRØNDAHL, Christian; Irisvej 19, DK-3500 Værløse (DK).**

(74) Common Representative: **NOVO NORDISK A/S; Novo Allé, DK-2880 Bagsværd (DK).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SAM**



(57) Abstract: Two receptors of meiosis activating sterols designated SAM1a and SAM1b have been identified.

Displacement of ³H-labelled
FF-MAS from SAM1b

WO 02/16432 A2

FIELD OF THIS INVENTION

5 The present invention relates to receptors or signalling proteins of FF-MAS, polynucleotides coding for receptors or signalling proteins of FF-MAS, probes hybridising with nucleic acids encoding receptors or signalling proteins of FF-MAS, DNA constructs comprising a sequence encoding receptors or signalling proteins of FF-MAS, culture cell lines wherein the DNA sequence encodes receptors or signalling proteins of FF-MAS, antibodies specifically
10 binding to receptors or signalling proteins of FF-MAS, hybridoma producing monoclonal antibodies specifically binding to receptors or signalling proteins of FF-MAS, and methods for detecting the presence of a compound having affinity to receptors or signalling proteins of FF-MAS.

15 BACKGROUND OF THIS INVENTION

Since the first IVF pregnancy was delivered in 1978, this procedure has resulted in thousands of pregnancies and opened a vast new frontier of research and treatment for the infertile couples. Still, there is a significant need for improved infertility treatment modalities today. It is presumed that about one out of seven couples experience problems with sub fertility or infertility.
20

IVF of human oocytes has become commonly used for the treatment of female and male sub fertility. The standard IVF treatment includes a long phase of hormone stimulation of the female patient. The aspirated oocyte is subsequently fertilised in vitro and cultured. Continuous efforts have been made to optimise and simplify this procedure. Nevertheless, the overall pregnancy rate cannot be increased significantly over about 20% with the current treatment modalities. In a large European survey of IVF patients, it was found that 7.2 oocytes out of 11.5 aspirated oocytes per patient had undergone resumption of meiosis immediately
25 before fertilisation, only 4.3 oocytes were fertilised and only 2.2 oocytes reached the 8-cell embryo stage after fertilisation and in vitro culture (ESHRE, Edinburgh, 1997).
30

Due to the very unpredictable quality of the state of the art embryos today, more than one embryo has to be transferred just to give a reasonable chance of success. Therefore, it is

common to transfer 2-3 embryos (up to 5 embryos in some countries), which carries the very large side effect of multiple pregnancies with great discomfort and risk to both patient and children. Moreover, it has been estimated that the increased health care expenses due to multiple birth (twins, triplets etc.) is exceeding the entire IVF expenses.

5

Hence, there are several disadvantages with the current treatment.

Furthermore, weight gain, bloating, nausea, vomiting, labile mood and other patient discomforts together with patient reluctance to inject themselves are reported as disadvantages.

10

It is known from WO 96/00235 that certain sterol derivatives can be used for regulating meiosis. An example of such a sterol is 4,4-dimethyl-5 α -cholesta-8,14,24-triene-3 β -ol (hereinafter designated FF-MAS).

15 Hence, at present, in vitro maturation in humans has proven highly unsuccessful despite substantial interest and clinical efforts.

One way of trying to find compounds which effectively regulate meiosis is the use of pertinent receptors.

20

Receptors are defined as proteinaceous macromolecules that perform a signal transducing function upon ligand binding. Many receptors are located on the outer cell membrane, others are located intracellularly. The substance which is bound by the receptor is called a ligand, a term which is definitionally meaningful only in terms of its counterpart receptor. The term "ligand" does not imply any particular molecular size or other structural or compositional feature other than that the substance in question is capable of binding, cleaving or otherwise interacting with the receptor in such a way that the receptor conveys information about the presence of the ligand to a target molecule. Stated alternatively, not all substances capable of binding a receptor are ligands, but all ligands are capable of binding a receptor. Receptors do not include such substances as immunoglobulins.

30

Receptors are believed to function by a process variously termed activation or signal transduction. A ligand binds to the ligand binding domain in such a way that the conformation of the receptor molecule changes. This conformational change, called activation, modifies the

effect of the receptor on cytoplasmic components. Among changes brought about by receptor activation are changes in or development of receptor enzymatic activity.

5 Signalling proteins such as cAMP, IP3, kinases, and phosphatases are proteins ubiquitously found in all tissues. These proteins cascade by various pathways, the stimulus from ligand/receptor interaction down stream to cellular events, typically changing the enzymatic activity or functional state of effector molecules.

10 The pharmaceutical industry in recent years has oriented its research to focus on the role of receptors in disease or injury and to design drugs, generally low molecular weight substances, that are capable of binding to the receptors. Drugs identified in this initial screen are then tested for the activity in vivo or in tissue explants. As a result, conventional techniques do not lend themselves to large-scale screening. Tissue samples or isolated cells containing the target receptors, for example ovarian tissue, are costly to obtain, present in limited quantity, and difficult to maintain in a functionally viable state. Additionally, it is often difficult to reliably and reproducibly administer the candidate drug to tissue samples. Screening assays using primary explants in tissue culture are undertaken in larger scale than is possible with tissue samples. However, it is more difficult to assay physiological effect and the assays are subject to interference from many sources, for example culture media or cultivation conditions. Finally, assays using receptors isolated from natural materials have the disadvantage that the receptor is subject to natural variability and suitable natural sources may not always be available. It is an object herein to provide readily reproducible, simple assay systems that can be practiced on a large scale for determining not only ligand binding but also the character of the binding as agonistic or antagonistic.

25 Similarly, meaningful clinical diagnosis often depends upon the assay of biologically active ligand without interference from inactive forms of the ligand, for example, ligands that have been subject to enzymatic or other processes in the test subject that change or even eliminate the activity of the ligand. Immunoassay methods are widely used in determining ligands in test samples. However, it is often quite difficult to identify antibodies that are able to discriminate between the active and inactive forms of a ligand. Receptors have frequently been used in place of antibodies as analyte binding reagents. However, not all substances that bind to receptors are necessarily capable of inducing receptor activity, i.e., active biologically. It is an object herein to provide a method that will identify ligands in clinical test sam-

30

ples which are active in inducing or inhibiting signal transduction by their receptors.

Cytoplasmic proteins can act as receptors or signalling molecules in cascading the stimulus from the ligand to cellular events. Various receptors or signalling protein types make use of
5 different path ways (for example small G proteins, calcium fluxes, phosphatases, and lipases), all of them resulting in changes of enzymatic activity or gene transcription.

Meiotic activating sterols (hereinafter designated MAS) constitute active signalling molecules first identified in follicular fluid and in bull testicular tissue. The sterols are described by By-
10 skov 1995 and Grøndahl et al. (*Biol. Reprod.* 58 (1998), 1297 *et seq.*) and in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically in Claim 1 thereof, as being potent activators of the meiotic process. No receptors or signalling proteins have been described to directly or indirectly signalling the meiotic effect of MAS sterols. Be-
fore this invention, the presence of the nature of a putative MAS receptor protein or a signal-
15 ling protein has not previously been identified, although its presence has been suggested, for example, by Grøndahl et al. (*Biol. Reprod.* 62 (2000), 775 *et seq.*).

On 29 September 2000, the nucleotide and amino acid sequence of clone NT2RM2001632 was released with accession number AK022554 and on 10 May 2001, the nucleotide and
20 amino acid sequence of clone NT2RP2000448 was submitted with accession number AK027535. No utility or action was mentioned for these clones.

There remains considerable need for an isolated and purified MAS receptor or a MAS signal-
ling protein, as well as systems capable of expressing a MAS receptor or a MAS signalling
25 protein separate from other receptors. Further, it would be desirable to specifically identify the presence of a MAS receptor or a MAS signalling protein in cells and tissues, thereby avoiding the time-consuming, complex and non-specific functional pharmacological assays. It would also be desirable to screen and develop new agonists and/or antagonists specific for
a MAS receptor or a MAS signalling protein for the use of antiinfertility or contraception
30 drugs, but to date this has not been possible. Quite surprisingly, the present invention fulfils these and other related needs.

SUMMARY OF THE INVENTION

Now, the present invention provides the nucleotide sequence of the receptors or signalling proteins of meiotic acting sterols (MAS). The present invention provides isolated and substantially pure MAS receptors or MAS signalling proteins and fragments thereof. These receptors or signalling proteins have been shown to be involved in the gamete maturation process induced by 3 β -hydroxy-4,4-dimethylcholest-8,14,24-triene (hereinafter designated FF-MAS), specifically inducing, upon ligand activation, germinal vesicle breakdown (hereinafter designated GVB) in mouse oocyte cultured in vitro. Hence, a MAS receptor or a MAS signalling protein is defined as a proteinaceous macromolecule that perform a signal transducing function upon binding to FF-MAS. Briefly, a MAS receptor or a MAS signalling protein binds to FF-MAS. Alternatively, a MAS signalling protein can be designated a MAS binding protein.

A MAS receptor is any protein related to the protein SAM1a or SAM1b that possess the same functional characteristic regarding the interaction with FF-MAS or other endogenous meiosis activating sterols, for example, 3 β -hydroxycholest-8,14-diene; 3 β -hydroxy-4,4-dimethylcholest-8,24-diene; and 3 β -hydroxycholest-8,24-diene, or their metabolites (as ligand). Functional characteristics include binding, receptor activation, and subsequent germinal vesicles breakdown (GVB) in oocytes. The amino acid sequence of SAM1a and SAM1b is stated in SEQ ID NO: 2 and SEQ ID NO: 4, below.

The MAS receptor can be used to discover profertility and antifertility compounds which can be used to men and women.

Having provided such receptors or signalling proteins in isolated or purified form, the invention also provides antibodies to the MAS receptor or signalling protein, in the form of antisera and/or monoclonal antibodies.

In another aspect, the invention provides the ability to produce the MAS receptor or MAS signalling protein and polypeptides or fragments thereof by recombinant means. The expressed MAS receptor or signalling protein or fragments may or may not have the biological activity of native receptor or signalling protein. Accordingly, isolated and purified polynucleotides are described which code for the receptor or signalling protein and fragment thereof, where the polynucleotides may be in the form of DNA, such as cDNA, or RNA. Based on

these sequences, probes may be used to hybridise and identify these and related genes which encode MAS receptors or MAS signalling proteins. The probes may be full length cDNA or as small as from 14 to 25 nucleotide, more often though from about 40 to about 50 or more nucleotides.

5

In related embodiments, the invention concerns DNA constructs which comprise a transcriptional promoter, a DNA sequence which encodes the receptor or signalling protein or fragment, and a transcriptional terminator, each operably linked for expression of the receptor or signalling protein. For expression, the construct may also contain at least one signal sequence. Further, for large-scale production, the expressed receptor or signalling protein may also be isolated from the cells by, for example, immunoaffinity purification.

Cells or bacteria which express the MAS receptor or MAS signalling proteins may also be used to identify compounds which can alter the receptor or signalling protein-mediated metabolism of a cell. Compounds may be screened for binding to the receptor or signalling protein, and/or for effecting a change in receptor or signalling protein-mediated metabolism in the host cell. Agonists and/or antagonists of the MAS receptor or MAS signalling proteins may also be screened in cell-free systems using purified receptor or signalling proteins or binding fragments thereof for the effect on ligand/receptor interaction or ligand/signalling protein interaction, or using reconstituted systems such as micelles which also provide the ability to assess metabolic changes.

In yet other embodiments, the invention relates to methods for diagnosis, where the presence of a mammalian MAS receptor or MAS signalling protein in a biological sample may be determined. For example, a monospecific antibody which specifically binds the receptor or signalling protein is incubated with the sample under conditions conducive to immune complex formation, which complexes are then detected, typically by means of a label such as an enzyme, fluorophore, radionuclide, chemiluminescer, particle, or a second labelled antibody. Thus, means are provided for immunohistochemical staining of tissues, including ovarian or testicular tissues, for the subject receptor or signalling proteins.

Based upon the similarity in sequence and the shared presence of a sterol binding domain at the protein level, the receptor proteins or signalling proteins of this invention can be said to belong to a novel super family of oxysterol binding proteins (hereinafter designated OSPB)

recently published in *J.Lipid.Res.* 40 (1999), 2204. No function whatsoever in gamete maturation of either gender or regulation of any meiotic processes has been assigned to this OSPB family.

5

BRIEF DESCRIPTION OF THE FIGURES

SEQ ID NO: 1 and SEQ ID NO: 3 are the nucleotides of the cDNA from two mouse MAS receptors or signalling peptides, designated SAM1a and SAM 1b, respectively, and having the amino acid sequences stated in SEQ ID NO: 2 and SEQ ID NO: 4, respectively. SEQ ID NO: 5 and SEQ ID NO: 7 are the nucleotides of the cDNA from two human MAS receptors or signalling peptides, designated SAM1a and SAM 1b, respectively, and having the amino acid sequences stated in SEQ ID NO: 6 and SEQ ID NO: 8, respectively. SEQ ID NO: 9 through 14 are the nucleotides referred to in example 5.

15

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention presents the means to identify agonists, and antagonists of the MAS receptor/ligand interaction or MAS signalling protein/ligand interaction by providing isolated MAS receptor or MAS signalling protein. The term "MAS receptor" refers to any proteins either derived from a naturally occurring MAS receptor, or which shares significant structural and functional characteristics peculiar to a naturally occurring MAS receptor. Such a receptor may result when regions of a naturally occurring receptor are deleted or replaced in such a manner as to yield a protein having a similar function. Homologous sequences, allelic variations, and natural mutants; induced point, deletion, and insertion mutants; alternatively expressed variants; proteins encoded by DNA which hybridise under high or low stringency conditions to nucleic acids which encode naturally occurring MAS receptor; proteins retrieved from naturally occurring materials; and closely related proteins retrieved by antisera directed against MAS receptor proteins are also included. Similarly, this applies to MAS signalling proteins.

30

By MAS receptor "ligand" is meant a molecule capable of being bound by the ligand-binding domain of MAS receptor, a MAS receptor analogue, or chimeric MAS receptor as generally

described in US Patent specification No. 4,859,609, incorporated by reference herein. The molecule may be chemically synthesised or may occur in nature. Ligands may be grouped into agonists and antagonists. Agonists are those molecules whose binding to a receptor induces the response pathway within a cell. Antagonists are those molecules whose binding to a receptor blocks the response pathway within a cell.

By "isolated" MAS receptor or MAS signalling protein is meant to refer to MAS receptor or MAS signalling protein which is in other than its native environment such as a mammalian oocyte, including, for example, substantially pure MAS receptor as defined herein below.

More generally, isolated is meant to include MAS receptor or MAS signalling protein as a heterologous component of a cell or other system. For example, MAS receptor or MAS signalling protein may be expressed by a cell transfected with a DNA construct which encodes MAS receptor or MAS signalling protein, separated from the cell and added to micelles which contain other selected receptor or signalling proteins. In some instances, the term MAS receptor covers both a MAS receptor and a MAS signalling protein.

By purified MAS receptor or MAS signalling protein is meant MAS receptor or MAS signalling protein having a purity of at least 50%, preferably at least 80%, more preferred at least 90% (w/w).

Human SAM1a and SAM 1b are the clones NT2RP2000448 and NT2RM2001632, respectively.

A similar way of defining the MAS receptors or MAS signalling proteins of the present invention is the similarity between the amino acid sequence of the various MAS receptors or MAS signalling proteins is at least about 90%, preferably about 95%, when compared with the amino acid sequence in SEQ ID NO: 2. Another expression of amino acid sequence similarity is homology. At the nucleotide level, the similarity between the nucleotides of the various MAS receptors or MAS signalling proteins is at least about 80%, preferably about 90%, when compared with the nucleotides in SEQ ID NO: 1.

One way of determining the affinity constant of a MAS receptor or a MAS signalling protein is by the test described in example 3, below. One way of determining whether FF-MAS binds to a specific MAS receptor is by the test described in example 4, below. The test described in

example 3 below can be used to determine whether a specific protein is a MAS receptor or a MAS signalling protein or, in other words, whether a specific protein is an analogue of SAM1a as specified in the claims below. In the present context, the term "analogue" is intended to indicate a naturally occurring variant (including one expressed in other animal species, for example, human, monkey, mouse or rat) of the MAS receptor or a "derivative", i.e., a polypeptide which is derived from the native MAS receptor by suitably modifying the DNA sequence coding for the variant, resulting in the addition of one or more amino acids at either or both the C- and N-terminal ends of the native amino acid sequence, substitution of one or more amino acids at one or more sites in the native amino acid sequence, deletion of one or more amino acids at either or both ends of the native sequence or at one or more sites within the native sequence, or insertion of one or more amino acids in the native sequence.

In another aspect, the invention provides means for regulating the MAS receptor/ligand interaction or MAS signalling protein/ligand interaction, and thus treating, therapeutically and/or prophylactically, a disorder which can be linked directly or indirectly to MAS receptor or MAS signalling protein or to its ligands, such as FF-MAS. By virtue of having the receptor or signalling protein of the invention, agonists or antagonists may be identified which stimulate or inhibit, respectively, the interaction of ligand with MAS receptor or with MAS signalling protein. With either agonists or antagonists, the metabolism and reactivity of cells which express the receptor or signalling protein are controlled, thereby providing a means to control meiosis in order to treat infertility or to achieve a novel principle of contraception.

Thus, the invention provides screening procedures for identifying agonists or antagonists of events mediated by the ligand/MAS receptor or ligand/MAS signalling protein interaction. Such screening assays may employ a wide variety of formats, depending to some extent on which aspect of the ligand, receptor or signalling protein interaction is targeted. For example, such assays may be designed to identify compounds which bind to the receptor or signalling protein and thereby block or inhibit interaction of the receptor or signalling protein and thereby block or inhibit interaction of the receptor or signalling protein with the ligand. Other assays can be designed to identify compounds which can substitute for ligand and therefore stimulate MAS receptor-mediated or MAS signalling protein-mediated intracellular pathways. Yet other assays can be used to identify compounds which inhibit or facilitate the association of MAS receptor or MAS signalling protein to FF-MAS and thereby mediate the cellular response to MAS receptor or MAS signalling protein ligand.

In one functional screening assay, the initiation of fertilisation activation events are monitored in eggs which have been injected with, for example, mRNA which codes for MAS receptor or MAS signalling protein and subsequently exposed to selected compounds which are being screened, in conjunction with or apart from an appropriate ligand. See generally, Kline *et al.*, *Science* 241 (1988), 464-467, incorporated herein by reference.

The screening procedure can be used to identify reagents such as antibodies which specifically bind to the receptor or signalling protein and substantially affect its interaction with ligand, for example. The antibodies may be monoclonal or polyclonal, in the form of antiserum or monospecific antibodies, such as purified antiserum or monoclonal antibodies or mixtures thereof. For administration to humans, for example, as a component of a composition for in vivo diagnosis or imaging, the antibodies are preferably substantially human to minimise immunogenicity and are in substantially pure form. By substantially human is meant generally containing at least about 70% human antibody sequence, preferably at least about 80% human, and most preferably at least about 90-95% or more of a human antibody sequence to minimise immunogenicity in humans.

Antibodies which bind to a MAS receptor or a MAS signalling protein may be produced by a variety of means. The production of non-human antisera or monoclonal antibodies, for example, murine, lagomorpha equine, etc. is well known and may be accomplished by, for example, immunising the animal with the receptor or signalling protein molecule or a preparation containing a desired portion of the receptor or signalling protein molecule, such as that domain or domains which contributes to ligand binding. For the production of monoclonal antibodies, antibody-producing cells obtained from immunised animals are immortalised and screened, or screened first for the production of antibody which binds to the receptor or signalling protein and then immortalised. As the generation of human monoclonal antibodies to human MAS receptor or MAS signalling protein antigen may be difficult with conventional techniques, it may be desirable to transfer antigen binding regions of the non-human antibodies, for example, the F(ab')₂ or hypervariable regions, to human constant regions (Fc) or framework regions by recombinant DNA techniques to produce substantially human molecules. Such methods are generally known in the art and are described in, for example, US patent specification No. 4,816,397, and EP publications 173,494 and 239,400, which are incorporated herein by reference. Alternatively, one may isolate DNA sequences which code

for a human monoclonal antibody or portions thereof that specifically bind to the human receptor or signalling protein by screening a DNA library from human B cells according to the general protocol outlined by Huse et al., *Science* 246 (1989), 1275-1281, incorporated herein by reference, and then cloning and amplifying the sequences which encode the antibody (or
5 binding fragment) of the desired specificity.

In other embodiments, the invention provides screening assays conducted in vitro with cells which express the receptor or signalling protein. For example, the DNA which encodes the receptor or signalling protein or selected portions thereof may be transfected into an estab-
10 lished cell line, for example, a mammalian cell line such as BHK and CHO, using procedures known in the art (see, for example, Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, which is incorporated herein by reference). The receptor or signalling protein is then expressed by the cultured cells, and selected agents are screened for the desired effect on the cell, sepa-
15 rately or in conjunction with an appropriate ligand such as FF-MAS or other MAS compounds. Means for amplifying nucleic acid sequences which may be employed to amplify sequences encoding the receptor or signalling protein or portions thereof are described in US patent specification Nos. 4,683,195 and 4,683,202, incorporated herein by reference.

In yet another aspect, the screening assays provided by the invention relate to transgenic mammals whose germ cells and somatic cells contain a nucleotide sequence encoding MAS receptor protein or signalling protein or a selected portion of the receptor or signalling protein which, for example, binds ligand. In yet a further aspect, the screening assays provided by the invention relate to transgenic mammals where the nucleotide sequence encoding a MAS
25 receptor or a MAS signalling protein is molecularly targeted to produce knock out animals with the phenotypical loss of the specific MAS signalling function. Preferentially, the molecular knock out is tissue specific to gonadal tissue (ovary or testes) and is timely controlled in the development, thus inducible. There are several means by which a sequence encoding, for example, the human MAS receptor may be introduced into a non-human mammalian
30 embryo or, alternatively, knocked out, some of which are described in, for example, US patent specification No. 4,736,866, Jaenisch, *Science* 240: 1468-1474 (1988) and Westphal et al., *Annu. Rev. Cell Biol.* 5: 181-196 (1989), which are incorporated herein by reference. The animal's cells then express the receptor or signalling protein and thus may be used as a convenient model for testing or screening selected agonists or antagonists.

In another aspect the invention concerns diagnostic methods and compositions. By means of having the MAS receptor or MAS signalling protein molecule and antibodies thereto, a variety of diagnostic assays are provided. For example, with antibodies, including monoclonal
5 antibodies, to MAS receptor or MAS signalling protein, the presence and/or concentration of receptor or signalling protein in selected cells or tissues in an individual or culture of interest may be determined. These assays can be used in the diagnosis and/or treatment of diseases such as, for example, male infertility, female infertility, or by means of contraception in both gender.

10 Numerous types of immunoassays are available and are known to those skilled in the art, for example, competitive assays, sandwich assays, and the like, as generally described in, for example US Patent specification Nos. 4,642,285; 4,376,110; 4,016,043; 3,879,262; 3,852,157; 3,850,752; 3,839,153; 3,791,932; and Harlow and Lane, *Antibodies, A Laboratory*
15 *Manual*, Cold Spring Harbor Publications, N.Y. (1988), each incorporated by reference herein. In one assay format, MAS receptor or MAS signalling protein is identified and/or quantified by using labelled antibodies, preferably monoclonal antibodies which are reacted with brain tissues, for example, ovarian or testicular tissue, oocyte preparations, or semen samples, and determining the specific binding thereto, the assay typically being performed
20 under conditions conducive to immune complex formation. Unlabeled primary antibody can be used in combination with labels that are reactive with primary antibody to detect the receptor or signalling protein. For example, the primary antibody may be detected indirectly by a labelled secondary antibody made to specifically detect the primary antibody. Alternatively, the anti-MAS receptor-antibody or MAS signalling protein-antibody can be directly labelled. A
25 wide variety of labels may be employed, such as radionuclides, particles (for example, gold, ferritin, magnetic particles, red blood cells), flourophores, chemilumescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, and ligands (particularly haptens).

The RNA encoding the MAS receptor MAS signalling protein may be directly detected in
30 cells with a labelled synthetic oligonucleotide probe targeting the MAS receptor RNA or MAS signalling protein RNA in a hybridisation procedure. Also, the polymerase chain reaction (Saiki *et al.*, *Science* 239 (1988), 487, and US patent specification No. 4,683,195, each reference is hereby incorporated by reference) may be used to amplify DNA sequences, which are subsequently detected by their characteristic size on agarose gels, Southern blot of

these gels using MAS receptor DNA or MAS signalling protein DNA or a oligonucleotide probe, or a dot blot using similar probes. The probes may comprise from about 14 nucleotides to about 25 or more nucleotides, preferably, 40 to 60 nucleotides, and in some instances a substantial portion or even the entire cDNA of MAS receptor or MAS signalling protein may be used. The probes are labelled with detectable signal, such as an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, and paramagnetic particle. High stringency in connection with hybridisation is obtained using the proper temperature and salt concentration.

Kits can also be supplied for use with the receptor or signalling protein of the subject invention in the detection of the presence of the receptor or signalling protein or antibodies thereto, as might be desired in the case of autoimmune disease. Thus, antibodies to MAS receptor or MAS signalling protein, preferably monospecific antibodies such as monoclonal antibodies, or compositions of the receptor or signalling protein may be provided, usually in lyophilised form in a container, either segregated or in conjunction with additional reagents, such as anti-antibodies, labels, gene probes, polymerase chain reaction primers and polymerase, and the like.

Even more specifically, the present invention relates to an isolated and/or purified polynucleotide molecule which hybridises at high stringency to an oligonucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which polynucleotide codes for a) a MAS receptor or for a MAS signalling protein; or b) a ligand binding domain of a MAS receptor or MAS signalling protein. This polynucleotide may be a RNA antisense sequence or a cDNA sequence. This polynucleotide may encode a polypeptide displaying MAS receptor or MAS signalling protein activity. This polynucleotide may encode a MAS receptor or MAS signalling protein (being able to bind to FF-MAS) having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. The polynucleotide may have the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.

Furthermore, this invention relates to a probe of at least 12 nucleotides, said probe being capable of hybridising with nucleic acids which encode a MAS receptor or MAS signalling protein. This probe may comprise an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 capable of specifically hybridising with a gene which encodes a MAS receptor or MAS signalling protein, or allelic and species

variants thereof. This probe may comprise from about 40 to about 60 nucleotides in length. This probe may be labelled to provide a detectable signal. This probe may comprise the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.

5 Furthermore, the present invention relates to a DNA construct comprising a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor or MAS signalling protein; or b) a ligand binding domain of a MAS receptor or MAS signalling protein. This DNA construct may have a DNA sequence encoding a MAS receptor
10 or MAS signalling protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

Furthermore, the present invention relates to a cultured cell line, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor or MAS signalling protein; or b) a ligand binding domain or a transmembrane domain of a MAS receptor or MAS signalling protein. This cell line, yeast or bacteria may not express endogenous MAS receptor or MAS signalling proteins.

20 The MAS receptor or MAS signalling protein, a peptide fragment thereof or a salt thereof according to the present invention may be isolated and/or purified. The isolated and/or purified protein (MAS receptor or MAS signalling protein) may comprise the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

25 Furthermore, the present invention relates to an isolated antibody which specifically binds to a MAS receptor or MAS signalling protein. In this isolated antibody said antibody may be a monoclonal antibody. This isolated antibody may block the binding of MAS to a MAS receptor or MAS signalling protein.

30 Furthermore, the present invention relates to a hybridoma which produces a monoclonal antibody as mentioned herein.

Furthermore, the present invention relates to a method for detecting the presence of a compound or a salt thereof which has affinity for a MAS receptor or MAS signalling protein, comprising the steps of a) contacting the compound with the MAS receptor or MAS signalling protein, a peptide fragment thereof or a salt thereof; and b) measuring the affinity of said
5 compound for the MAS receptor or MAS signalling protein. This method for detecting the presence of MAS antagonists, may comprise the steps of a) exposing a compound in the presence of a MAS agonist including MAS (FF-MAS) to a MAS receptor or MAS signalling protein coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor or MAS signalling protein and an associated
10 response through the pathway; and b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor or MAS signalling protein, relative to the stimulation of the response pathway by the MAS agonist alone and there from determining the presence of a MAS antagonist. Furthermore, a method for detecting the presence of MAS agonists, may comprise the steps of a) exposing a com-
15 pound in the presence of a MAS antagonist to a MAS receptor or MAS signalling protein coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor or MAS signalling protein and an associated response through the pathway; and b) detecting an increase of the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor or MAS signalling pro-
20 tein, relative to the stimulation of the response pathway by the MAS antagonist alone and there from determining the presence of a MAS agonist.

Furthermore, the present invention relates to a compound or a salt thereof which has affinity for the MAS receptor or a MAS signalling peptide and which compound or salt is detected by
25 a method described herein.

Furthermore, the present invention relates to a method for producing a MAS receptor or MAS signalling protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which may comprise a) growing cells, yeast or bacteria transformed or transfected with a
30 DNA construct which comprises a DNA sequence of SEQ ID NO: 1 or SEQ ID NO: 3 coding for the expression of the MAS receptor or MAS signalling protein, and b) isolating the MAS receptor or MAS signalling protein from the cells. In this method, the MAS receptor or MAS signalling protein may be isolated by immunoaffinity purification.

Furthermore, the present invention relates to a kit for screening a compound or a salt thereof which has affinity for a MAS receptor or MAS signalling protein, which contains the MAS receptor or MAS signalling protein, the peptide fragment thereof or a salt thereof.

- 5 Alternatively, the MAS receptor or MAS signalling protein may be defined as one which comprises the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling protein comprising the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10
- 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. Alternatively, the MAS receptor or MAS signalling protein may comprise the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling protein comprising the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with
- 15 an affinity constant below 100 μM , preferably below 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. Alternatively, the MAS receptor or MAS signalling protein may comprise the partial amino acid sequence shown in SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling protein comprising the partial amino acid sequence shown in
- 20 SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. Alternatively, the MAS receptor or MAS signalling protein may comprise the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling
- 25 protein comprising the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. The MAS receptor or MAS signalling protein according to the present invention may be a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay.
- 30 The MAS receptor or MAS signalling protein being a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay, may be different from the amino acid sequence in SEQ ID NO: 6 and 8.

Furthermore, the present invention relates to a DNA construct which comprises a DNA sequence encoding a MAS receptor or MAS signalling protein as described herein or a DNA sequence coding for a functional analog thereof binding to FF-MAS. The DNA construct comprises a DNA sequence encoding a MAS receptor or MAS signalling protein as defined herein
5 or a DNA sequence coding for a functional analog thereof binding to FF-MAS may be different from the nucleotides of SEQ ID NO: 5 and 7. The DNA construct of the present invention may comprise the DNA sequence shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M. This DNA construct comprising the DNA sequence
10 shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, may be different from the nucleotides of SEQ ID NO: 5 and 7. The DNA construct according to the present invention may comprise the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M. This DNA construct comprising the partial DNA
15 sequence shown in SEQ ID NO: 5, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, may be different from the nucleotides of SEQ ID NO: 5 and 7.

20 Furthermore, the present invention relates to a recombinant expression vector which carries an inserted DNA construct according to any one of the preceding claims to a DNA construct.

Furthermore, the present invention relates to a cell containing a recombinant expression vector as defined herein. This cell may contain a DNA construct as defined herein integrated in its genome. This cell may be a eukaryotic cell, in particular an insect or a mammalian cell.
25

Furthermore, the present invention relates to a method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-MAS activity, the method comprising incubating a MAS receptor or MAS signalling protein as defined herein with a substance suspected to be
30 an agonist or antagonist of FF-MAS, and subsequently with FF-MAS, or an analogue thereof, and detecting any effect of binding of FF-MAS, or the analogue to the MAS receptor or MAS signalling protein. Alternatively, the method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-MAS activity, may comprise incubating FF-MAS, or an analogue thereof with a substance suspected to be an agonist or antagonist of activity of FF-MAS, and

subsequently with a MAS receptor or MAS signalling protein as described herein, and detecting any effect of binding of FF-MAS, or the analogue to the receptor.

Furthermore, the present invention relates to the use of a MAS receptor or MAS signalling protein as defined herein for screening for agonists or antagonists of activity of FF-MAS.

Furthermore, the present invention relates to the use of DNA constructs as defined herein for isolation of tissue and/or organ specific variants of the MAS receptor or MAS signalling protein.

Furthermore, the present invention relates to the use of a MAS receptor or MAS signalling protein isolated as described herein.

The following examples are offered by way of illustration, not by limitation.

EXAMPLE 1

Microinjection of phosphorothionate oligonucleotides into mouse oocytes

Two antisense oligonucleotides (20 nucleotides) were utilized for microinjection: 5'-TCCAC-GATGGACGCCATCTT-3' and 5'-GCCAGCAGGAGAGCCATTCG-3', complementary to the kozak sequence of the mRNA encoded by the cDNA sequence herein designated SAM1a and SAM1b, respectively, both of which are defined in SEQ ID NO: 1 and SEQ ID NO: 3, respectively, shown below. In control experiments, the corresponding sense oligonucleotides were microinjected: 5'-AAGATGGCGTCCATCGTGGA-3' and 5'-CGAATGGCTCTC-CTGCTGGC-3' for mRNA SAM1a and SAM1b, respectively. SAM1a antisense was co-injected with SAM1b antisense from a stock solution containing 1.25 µg/µl of each nucleotide in 10 % human serum albumin (hereinafter designated HSA) plus 5 mM Tris (pH value: 7.5). SAM1a sense was co-injected with SAM1b sense from a stock solution containing 1.25 µg/µl of each nucleotide in 10 % HSA plus 5 mM Tris (pH value: 7.5). Approximately 12 pg of each oligonucleotide (10 pl) were injected into the cytoplasm of individual germinal vesicle (GV)-stage oocytes loaded in a droplet of alpha-MEM supplemented with 0.8% HSA and 3 mM hypoxanthine under mineral oil in a 35 mm petri dish on the stage of an inverted micro-

scope. The oocytes were obtained from the ovaries of 21-24 days old mice following 48 hours priming with follicle stimulating hormone (hereinafter designated FSH) as described by Grøndahl *et al.* 1998 in *Biol. Reprod.* 58 (1998), 1297 *et seq.* Oocytes were sucked on to a holding pipette (120 μ M outer diameter and 20 μ M inner diameter) and an injection pipette (Eppendorph, Hamburg, Germany) was fitted to a pressure microinjector (Eppendorph, Hamburg, Germany). The pipette holder was attached to a piezoelectric positioning system (Burleigh, NY, USA) mounted on a motorized micromanipulator (Luigs and Neumann, Ratingen, Germany). The injection pipette was pushed against the zona pelludica, and then a piezoelectric pulse was given, moving the injection pipette 20 μ M forward. During this movement the pipette penetrated the zona pelludica and oolema and then a brief pressure pulse was applied to release a volume of approximately 10 μ l into the oocytes cytoplasm. Injected oocytes were placed in a CO₂ incubator at 37°C for 20 hours before resumption of meiosis was triggered by addition of 10 μ M FF-MAS to the hypoxanthine containing medium. The effect of FF-MAS was evaluated after 24 hours of further incubation as the number of oocytes in germinal vesicle breakdown (hereinafter designated GVBD). The rationale for the 20 hours cultivation period following injection of antisense oligonucleotides is to allow for degradation of mRNA coding for SAM1a and SAM1b protein. Consequently, when the level of MAS receptor protein or MAS signalling protein is reduced in the oocytes, the MAS response is blunted (from 100% to 50%, vide the table below).

Table 1

Oligonucleotide	GVBD/GVBD+GV 10 μ M FF-MAS (24 hours)
SAM1a + SAM1b	13/25
Antisense	
SAM1a + SAM1b	10/10
Sense	
Non-injected oocytes	26/29

As shown in Table 1, GVBD was inhibited by 50% in antisense injected oocytes compared to control (i.e., sense injected and non-injected oocytes). This result indicates a selective inhibition of the mRNAs coding for SAM1a and SAM1b by the antisense probe. Furthermore, these results indicate that SAM1a and SAM1b proteins are crucial involved in the MAS sig-

nalling, since a functional knock out of *de novo* protein synthesis of these molecules partly disrupt the MAS signals in oocytes.

SAM1a and SAM1b are two closely related proteins originating from the same gene which
5 possesses complementary functions regarding MAS signalling in oocytes.

Example 2

10 FF-MAS binding assay:

10 µl of the unlabelled FF-MAS (1, 3, 10, 30, 100, 300, 1000, 3000 nM in 6.6% ethanol (EtOH)) was mixed with 10 µl of 200 nM ³H-labelled FF-MAS (approximately 12.8 Ci/mmol) in assay buffer (10 mM Tris; 1.5 mM EDTA; 10% glycerin; 1.0 mM 3-(3-cholamidopropyl)di-
15 methylamino-1-propanesulphonate (hereinafter designated CHAPS, Boehringer Mannheim); 1% BSA (bovine serum albumin)). 10 µg of SAM1b protein freshly diluted in assay buffer, was added to give a final volume of 40 µl. Unspecific binding was measured in the presence of 30 µM unlabelled FF-MAS, total binding was determined by adding 10 µl assay buffer containing 6.6% EtOH. Incubation was performed for 2 hours at 4°C. 250 µl of ice-cold assay
20 buffer containing 2% Cab-osil M-5 (silica gel from Fluka) and 0.2% dextran T70 (Sigma) was added to each tube, mixed and spun briefly. Approximately 5 minutes after adding Cab-osil M-5, the tubes were centrifuged for 5 minutes, 14000 rpm (minifuge). 200 µl of the supernatant was transferred to a microscint-tube and 3.5 ml atomlight (Packard) was added. Tubes were measured in a liquid scintillation counter. The results obtained are shown in Figure 1. "IC-50" is the concentration of unlabelled FF-MAS which displaces 50% of the bound
25 ³H FF-MAS.

Example 3

30

Assay to determine whether a specific polynucleotide encodes a protein which is a MAS receptor or a MAS signalling protein:

10 µl of the unlabelled FF-MAS (1, 3, 10, 30, 100, 300, 1000, 3000 nM in 6.6% EtOH) is mixed with 10 µl of 200 nM ³H-labelled FF-MAS (approximately 12.8 Ci/mmol) in assay buffer (10 mM Tris; 1.5 mM EDTA; 10% glycerin; 1.0 mM CHAPS; 1% BSA). 10 µg of the specific protein to be tested freshly diluted in assay buffer, is added to give a final volume of 40 µl. Unspecific binding is measured in the presence of 30 µM unlabelled FF-MAS, total binding is determined by adding 10 µl assay buffer containing 6.6 % EtOH. Incubation is performed for 2 hours at 4°C. 250 µl of ice-cold assay buffer containing 2 % Cab-osil M-5 and 0.2 % dextran is added to each tube, mixed and spinned briefly. Approximately 5 minutes after adding Cab-osil M-5, the tubes are centrifuged for 5 minutes, 14000 rpm (minifuge). 200 µl of the supernatant is transferred to a microscint-tube and 3.5 ml atomlight is added. Tubes are measured in a liquid scintillation counter. If ³H FF-MAS binding can be displaced by unlabelled FF-MAS, then the protein tested is a MAS receptor or a MAS signalling protein.

Example 4

Assay to determine whether a specific compound is a ligand:

10 µl of the compound to be tested (1, 3, 10, 30, 100, 300, 1000, 3000 nM in 6.6% EtOH) is mixed with 10 µl of 200 nM ³H-labelled FF-MAS (approximately 12.8 Ci/mmol) in assay buffer (10 mM Tris; 1.5 mM EDTA; 10% glycerin; 1.0 mM CHAPS; 1% BSA). 10 µg of SAM1a protein freshly diluted in assay buffer, is added to give a final volume of 40 µl. Unspecific binding is measured in the presence of 30 µM unlabelled FF-MAS, total binding is determined by adding 10 µl assay buffer containing 6.6% EtOH. Incubation is performed for 2 hours at 4°C. 250 µl of ice-cold assay buffer containing 2 % Cab-osil and 0.2% dextran is added to each tube, mixed and spinned briefly. Approximately 5 minutes after adding Cab-osil, the tubes are centrifuged for 5 minutes, 14000 rpm (minifuge). 200 µl of the supernatant is transferred to a microscint-tube and 3.5 ml atomlight is added. Tubes are measured in a liquid scintillation counter. If a compound can displace specific FF-MAS binding, then it is a ligand to the MAS receptor or to a MAS signalling protein.

Example 5

Cloning of SAM1

An cDNA library was prepared from mRNA isolated from 10,000 oocytes, from 24 days old mice. The cDNA library was constructed in the pSPORT plasmid vector (LifeTechnologies).
5 Clones were picked at random and partially sequenced, and the sequences were assembled using phred/phrap programs. Out of several thousand clones that were sequenced, an assembly of two exhibited 21 % amino acids identity to a human Oxysterol Binding Protein. The longest clone MOCY2864 was completely sequenced and no identical or orthologous genes were found in the databases. This new gene was named SAM1. Amplification of the 5'
10 end of SAM1 cDNA was performed by PCR on the oocyte library using a primer specific for pSPORT, #176959 (SEQ ID NO: 9) and a primer specific for SAM1 #198241 (SEQ ID NO: 10). This revealed cDNAs with two different 5' ends, which were designated SAM1a and SAM1b. Full-length PCR amplification was done on the mouse oocyte library using primer #199772 (SEQ ID NO: 11) and #198239 (SEQ ID NO: 12) for SAM1a and #201790 (SEQ ID
15 NO: 13) and #198239 (SEQ ID NO: 12) for SAM1b. Recognition sites for NheI and NotI, respectively, were incorporated in the primers. SAM1a and SAMb cDNAs were digested with NheI and NotI restriction enzymes and cloned into pcDNA3,1+ (Invitrogen).

DNA constructs directing the expression of SAM1a and SAM1b proteins fused to a C-
20 terminal histidine stretch, which could be used for in purification because of its affinity to nickel-columns were made as follows. SAM1a and SAM1b cDNAs were PCR amplified using the primers #199772 (SEQ ID NO: 11) and #211465 (SEQ ID NO: 14) and primers #201790 (SEQ ID NO: 13) and #211465 (SEQ ID NO: 14), respectively. Recognition sites for NheI and XmaI, respectively, were incorporated in the primers. The PCR-products were then
25 cloned into pBlueBac4,5V5HIS (Invitrogen) using the restriction enzymes NheI and XmaI. This intermediate construct was then digested by SmaI and BstBI, filled-in using the Klenow fragment of DNA polymerase1 and then religated. These construct were designated "SAM1a in pBlueBac4,5V5HIS" and "SAM1b in pBlueBac4,5V5HIS".

30

SAM1 expression in Sf9 cells

SAM1a-HIS and SAM1b-HIS proteins were expressed using recombinant Baculo virus in Sf9 cells according to the "Bac-N-Blue™ Transfection Kit" manual (Invitrogen).

To infect Sf9 insect cells 0,5 µg Bac-N-Blue™ DNA and the recombinant transfer plasmid "SAM1 in pBlueBac4,5V5HIS" (4 µg) were incubated with 1 ml Grace's Insect Media and and 20 µl Insectin-Plus Liposomes for 15 minutes, then the mixture was added to 2×10^6 Sf9 cells
5 in a 60 mm dish. The cells were left for 96 hours rocking at 27°C. Vira were isolated and plaque assay was performed. Putative recombinant plaques were picked and P-1 viral stocks were made. PCR analysis of recombinant viral clones was done and from positive clones high-titer viral stocks were then prepared. For large-scale SAM1a and SAM1b expression 500 ml Sf9 cells ($2,0 \times 10^6$ cells/ml) was infected with 25 ml virus ($1,8 \times 10^8$ plaque
10 forming units/ml) or 60 ml virus (6×10^7 pfu/ml) for SAM1a and SAM1b, respectively. After 70 hours of incubation the cells were pelleted by centrifugation and the protein was purified.

SEQ ID NO: 9

15 CCAAGCTCTAATACGACTCAC

SEQ ID NO: 10

CTCAGCCACAAATGTTACAC

20 SEQ ID NO: 11

CTAGCTAGCACCATGGCGTCCATCGTGGAAGG

SEQ ID NO: 12

ATAAGAATGCGGCCGCGAGGAGAAAAGGGAAGCGG

25

SEQ ID NO: 13

CTAGCTAGCACCATGGCTCTCCTGCTGGCCGCTTG

SEQ ID NO: 14

30 CCCGGGCATGCTTCACAGCACCAAGACGC

Example 6

Purification of SAM1a and SAM1b

Purification of HIS-SAM1a and HIS-SAM1b was performed according to the manual of QIAGEN: The QIAexpressionist forth edition.

- 5 Briefly, cell cultures of SF9 insect cells (containing the construct for 6xHis-SAM1a or 6xHis-SAM1b in a baculovirus expression vector) were centrifuged, pellets were lysed by addition of lysis buffer (50 mM NaH_2PO_4 , 300 mM NaCl, 10 mM imidazole, pH 8) and lysozyme, sonication on ice 6 x 10 seconds, where after the lysates were cleared by centrifugation.
- 10 Cleared lysates were incubated under mild agitation with 50% slurry of Ni-NTA agarose (QIAGEN), for binding of 6xHis-SAM1a, washed twice (50 mM NaH_2PO_4 , 300 mM NaCl, 20 mM imidazole, pH 8) and eluted with high concentration of imidazole (50 mM NaH_2PO_4 , 300 mM NaCl, 250 mM imidazole, pH 8). Purified proteins were analysed on Coomassie (Brilliant Blue, Sigma) stained SDS-polyacrylamide gels (NuPAGE 4-12% Bis-Tris gel, Invitrogen)
- 15 (gen) for evaluation of yield and purity.

SEQ ID NO: 1

SAM1a DNA

5 TTTGTTGTCATTGGCGGCTCCCAAGATGGCGTCCATCGTGGAAGGGCCGCTGAGCAAA
TGGACTAACGTGATGAAGGGATGGCAGTATCGTTGGTTCGTGCTGGACTACAATGCAG
GGCTGCTCTCCTACTACACGTCCAAGGACAAAATGATGAGAGGCTCTCGAAGAGGATG
CGTTAGACTCAGAGGAGCTGTGATTGGTATAGACGACGAGGACGACAGCACCTTCACA
ATCACTGTGATCAGAAAACCTTCCACTTCCAGGCTCGAGATGCAGACGAGCGAGAGA
10 AGTGGATCCATGCCTTAGAAGAACTATTCTTCGCCATACTCTTCAGCTTCAAGGTTTG
GATTCAGGATTCATCCCCAGTGTCCAAGACTTTGATAAGAACTTACCGAGGCTGACGC
GTACCTGCAGATCTTGATAGAACAATTAAAGCTTTTTGATGACAAGCTTCAAAATTGTAA
AGATGATGAACAGAGAAAAGAAAGTTGAACTCTCAAAGACACAACAAATAGCATGGTAG
AATCAATTAACACTGCATTGTGTTGCTACAGATTGCTAAAAGTACTATTAATCCTGTAG
15 ATGCAATATACCAGCCTAGTCCCTTGGAACCTGTGATCAGCACAATGCCTTCCCAGACT
GCCTTACCTCCAGAACCCGCTCAGTTGTGTAAGTCAGAGCAGCGTCCATCTTCCTTACC
TGTTGGACCTGTGTTAGCTACCTTGGGACATCATCAGACTCCAACACCAAATAGTACAG
GCAGTGGGAACCTACCCACCTAGCAGCAGTCTGACTCCTCCCAGCCATGTCAACTTGTC
TCCAAATACAGTCCCAGAGTTCTCTTACTCTAGCAGTGAAGATGAGTTCTATGATGCTG
20 ATGAATTCCATCAAAGTGGCTCGTCCCCAAAGCGCTTAATAGATTCTTCTGGATCTGCC
TCAGTCTTGACACACAGCAGCTCCGGAAATAGCTTAAACGCCCAGATACCACAGAGTC
TCTGAATTCCTCCATGTCCAATGGCACAAGCGATGCTGATCTTTTTGACTCACATGACG
ACAGAGATGATGATGGGGAGGCTGGGTGAGTGGAGGAGCACAAGAGCGTTATCATGC
ACCTCTTATCACAAGTCAGGCTGGGGATGGACCTCACAAAGGTAGTTCTTCCAACGTTT
25 ATTCTCGAGAGAAGATCTCTGTTAGAAATGTATGCAGACTTTTTCGCACATCCAGACCT
GTTGCGTGAGCATTAGTGATCAGAAGGATCCCAGGGATCGAATGGTTCAGGTTGTGAAA
TGGTACCTCTCGGCCTTCCATGCAGGAAGGAGAGGATCGGTGGCCAAAAGCCGTACA
ATCCTATTTTGGGTGAGATCTTTCAGTGTCACTGGACGTTGCCGAATGATACTGAAGAG
AACGCAGAGCTCGTTTCAGAAGGGCCGGTCCCTGGGTTTCTAAGAACAGTGTAACATT
30 TGTGGCTGAGCAAGTTTCCCACCATCCGCCATTTTCAGCCTTTTATGCTGAGTGTTTA
ACAAGAAGATACAATTCAATGCTCATATCTGGACTAAATCAAAATTCCTTGGGATGTCAA
TTGGGGTACACAACATAGGTCAGGGCTGTGTCTCGTGTCTGGAGTACGATGAGCACTA
CATCCTCACGTTCCCCAATGGCTATGGAAGGTCTATCCTGACAGTGCCCTGGGTGGAA
TTGGGAGGAGAATGCAATATCAACTGCTCCAAAACGGGTACAGCGCAAACATCGTCTT
35 CCACACTAAGCCTTTCTATGGGGGCAAGAAGCACAGAATTACTGCAGAGATTTTTTCTC

CGAATGACAAGAAATCCTTCTGCTCAATTGAAGGGGAATGGAATGGTATCATGTATGC
AAAATACGCAACAGGGGAAAACACTGTCTTTGTAGACACCAAGAAATTGCCTATAATCA
AGAAAAAGGTGAGGAAGTTGGAAGATCAGAATGAGTATGAGTCCCGCAGCCTTTGGAA
GGATGTCACCTTCAATTTAAAAATCAGAGACATTGATGCAGCAACGGAAGCAAAGCACA
5 GACTTGAAGAAAGACAAAGAGCAGAAGCCCGAGAAAGGAAGGAGAAGGAAATTCAGTG
GGAGACGAGGCTCTTTCACGAGGATGGCGAATGCTGGGTTTACGATGAGCCTTTACTG
AAGCGTCTTGGTGCTGTGAAGCATTAGGCCGACAACCGAGTCCACACCTGGTGACCAG
GGCAGTAGGCGTAATTAAGCAACAATCGATCTTCCTTCAGGAGAGCTTGTCACCTTCCTT
CTTAACGCAGTGGTTCCTATCTCAGGGATACTGGACTTGACGACACAGATGAACAATTA
10 AAGTGGAAACCGCTTCCCTTTTCTCCTCTGTGGCAGTTACAATTTTGACTTCAGGCCTG
AGAAAACTTCAGGTTTCGAAACATGACATCTTCCCTTTTCCAGATCCCATGCTTTGAA
AAATATTTATAGACAGTTCCAGGTCTCAGCTTCCTGTCCTCTAGTTCTGCTGTTCCGGGC
ATAAAATCTTTATCTCCAGTTCATATAATCTTGAGTTTTAGATAKACACACATGCGTAACA
GCTGACAGTTTTTTCACAAGTACACCCACCTGTAAATACTGTAKCCTCAGTTTAGAAAATT
15 AGTGCATGTATGAAAATCAAGTGTTAGGAAATTCATGGTTTCACCTATAACCTTTATTTT
AGAATTGAACTATGATTAGATTGTATCTAAACCTGAAGTATAATTATATGCAGTGCTTCTT
AAGGCTTCATAAAATAATTTTCCAACCTTTTTAAAAAAAAAAAAAAAAA

SEQ ID NO: 2

SAM1a peptide

5 MASIVEGPLSKWTNVMKGWQYRWFVLDYNAGLLSYYTSKDKMMRGSRRGCVRLRGAVIG
IDDEDDSTFTITVDQKTFHFQARDADEREKWIHALEETILRHTLQLQGLDSGFIPSVQDFDKK
LTEADAYLQILIEQLKFDDKLQNCKDDEQRKKVETLKDTTNSMVESIKHCIVLLQIAKSTINPV
DAIQPSPLEPVISTMPSQTALPPEPAQLCKSEQRPSLPVGPVLATLGHHQTPTPNSTGSG
NSPPSSSLTPPSHVNLS PNTVPEFSYSSSEDEFYDADEFHQSGSSPKRLIDSSGSASVLTHS
10 SSGNSLKRPDTTESLNSSMSNGTSDADLFD SHDDRDDDGEAGSVEEHKSVIMHLLSQVRL
GMDLTKVVLPTFILERRSLLEMYADFFAHPDLFVSISDQKDPRDRMVQVWKWYLSAFHAGR
RGSVAKKPYNPILGEIFQCHWTL PNDTEENAELVSEGPVPWVSKNSVTFVAEQVSHHPPIS
AFYAECFNKKIQFNAHIWTKSKFLGMSIGVHNIGQGCVSCLEYDEHYILTFPNGYGRSILTP
WVELGGECNINCSKTGYSANIVFHTKPFYGGKKHRITAEIFSPNDKKSFC SIEGEWNGIMYA
15 KYATGENTVFVDTKKLPIKKKVRKLEDQNEYESRSLWKDVT FNLKIRDIDAATEAKHRLEER
QRAEARERKEKEIQWETRLFHEDGE CWVYDEPLLKRLGAVKH

SEQ ID NO: 3

SAM1b DNA

5 GGGCCCCTCCCCTGAGACGGCGGCCGGCCGCCGCGAATGGCTCTCCTGCTGGCCGC
TTGCGGAGGTTTGGATTGAGGATTCATCCCCAGTGTCCAAGACTTTGATAAGAACTTA
CCGAGGCTGACGCGTACCTGCAGATCTTGATAGAACAATTAAGCTTTTTGATGACAAG
CTTCAAAATTGTAAAGATGATGAACAGAGAAAGAAAGTTGAAACTCTCAAAGACACAACA
AATAGCATGGTAGAATCAATTAACACTGCATTGTGTTGCTACAGATTGCTAAAAGTACT
10 ATTAATCCTGTAGATGCAATATACCAGCCTAGTCCCTTGGAACCTGTGATCAGCACAAT
GCCTTCCCAGACTGCCTTACCTCCAGAACCCGCTCAGTTGTGTAAGTCAGAGCAGCGT
CCATCTTCCTTACCTGTTGGACCTGTGTTAGCTACCTTGGGACATCATCAGACTCCAAC
ACCAAATAGTACAGGCAGTGGGAACTCACACCTAGCAGCAGTCTGACTCCTCCCAGC
CATGTCAACTTGTCTCCAAATACAGTCCCAGAGTTCTTACTCTAGCAGTGAAGATGA
15 GTTCTATGATGCTGATGAATTCCATCAAAGTGGCTCGTCCCCAAAGCGCTTAATAGATT
CTTCTGGATCTGCCTCAGTCTTGACACACAGCAGCTCCGGAAATAGCTTAAAACGCCCA
GATACCACAGAGTCTCTGAATTCCTCCATGTCCAATGGCACAAGCGATGCTGATCTTTT
TGA CTCACATGACGACAGAGATGATGATGGGGAGGCTGGGTGAGTGGAGGAGCACAA
GAGCGTTATCATGCACCTCTTATCACAAGTCAGGCTGGGGATGGACCTCACAAAGGTA
20 GTTCTTCCAACGTTTATTCTCGAGAGAAGATCTCTGTTAGAAATGTATGCAGACTTTTTC
GCACATCCAGACCTGTTGCGTGAGCATTAGTGATCAGAAGGATCCCAGGGATCGAATGG
TTCAGGTTGTGAAATGGTACCTCTCGGCCTTCCATGCAGGAAGGAGAGGATCGGTGGC
CAAAAAGCCGTACAATCCTATTTTGGGTGAGATCTTTCAGTGTCACTGGACGTTGCCGA
ATGATACTGAAGAGAACGCAGAGCTCGTTTCAGAAGGGCCGGTTCCTGGGTTTCTAA
25 GAACAGTGTAACATTTGTGGCTGAGCAAGTTTCCCACCATCCGCCCATTTTCAGCCTTTT
ATGCTGAGTGTTTAAACAAGAAGATACAATTCAATGCTCATATCTGGACTAAATCAAAAT
TCCTTGGGATGTCAATTGGGGTACACAACATAGGTGAGGGCTGTGTCTCGTGTCTGGA
GTACGATGAGCACTACATCCTCACGTTCCCCAATGGCTATGGAAGGTCTATCCTGACAG
TGCCCTGGGTGGAATTGGGAGGAGAATGCAATATCAACTGCTCCAAAACGGGTACAG
30 CGCAAACATCGTCTTCCACACTAAGCCTTTCTATGGGGGCAAGAAGCACAGAATTACTG
CAGAGATTTTTTCTCCGAATGACAAGAAATCCTTCTGCTCAATTGAAGGGGAATGGAAT
GGTATCATGTATGCAAAATACGCAACAGGGGAAAACACTGTCTTTGTAGACACCAAGAA
ATTGCCTATAATCAAGAAAAAGGTGAGGAAGTTGGAAGATCAGAATGAGTATGAGTCCC
GCAGCCTTTGGAAGGATGTCACCTTTCAATTTAAAAATCAGAGACATTGATGCAGCAACG
35 GAAGCAAAGCACAGACTTGAAGAAAGACAAAGAGCAGAAGCCCGAGAAAGGAAGGAGA

AGGAAATTCAGTGGGAGACGAGGCTCTTTCACGAGGATGGCGAATGCTGGGTTTACG
ATGAGCCTTTACTGAAGCGTCTTGGTGCTGTGAAGCATTAGGCCGACAACCGAGTCCA
CACCTGGTGACCAGGGCAGTAGGCGTAATTAAGCAACAATCGATCTTCCTTCAGGAGA
GCTTGTCACCTTCCTTCTTAACGCAGTGGTTCCTATCTCAGGGATACTGGACTTGACGAC
5 ACAGATGAACAATTAAAGTGGAACCGCTTCCCTTTTCTCCTCTGTGGCAGTTACAATTT
TGACTTCAGGCCTGAGAAAACTTCAGGTTTCGAAACATGACATCTCTTCCTTTTCCAGA
TCCCATGCTTTGAAAAATATTTATAGACAGTTCCAGGTCTCAGCTTCCTGTCCTCTAGTT
CTGCTGTTCTGGGCATAAAATCTTTATCTCCAGTTCATATAATCTTGAGTTTTAGATAKAC
ACACATGCGTAACAGCTGACAGTTTTTCAAGTACACCCACCTGTAAATACTGTAKCCT
10 CAGTTTAGAAAATTAGTGCATGTATGAAAATCAAGTGTTAGGAAATTTTCATGGTTTCACC
TATAACCTTTATTTTAGAATTGAACTATGATTAGATTGTATCTAAACCTGAAGTATAATTA
TATGCAGTGCTTCTTAAGGCTTCATAAAATAATTTTCCAACCTTTTTAAAAAAAAAAAAAA
A

SEQ ID NO: 4

SAM1b peptide

5 MALLLAACGGLD SGFIPSVQDFDKKLTEADAYLQILIEQLKLFDDKLQNCKDDEQRKKVETLK
DTTNSMVESIKHCIVLLQIAKSTINPVDAIYQSPLEPVISTMPSQTALPPEPAQLCKSEQRPS
SLPVGPVLATLGHHQTPTPNSTGSGNSPPSSSLTPPSHVNLS PNTVPEFSYSSSEDEFYDA
DEFHQSGSSPKRLIDSSGSASVLTHSSSGNSLKRPDTTESLNSSMSNGTSDADLFDSHDDR
DDDGEAGSVEEHKSVIMHLLSQVRLGMDLTKVVLPTFILERRSLLEMYADFFAHPDLFVSISD
10 QK DPRDRMVQVVKWYLSAFHAGRRGSVAKKPYNPILGEIFQCHWTL PNDTEENAELVSEG
PVPWVSKNSVT FVAEQVSHHPPISAFYAECFNKKIQFN AHIWTKSKFLGMSIGVHNIGQGCV
SCLEYDEHYILTFPNGYGRSILTPWVELGGE CNINCSKTGYSANIVFHTKPFYGGKKHRITA
EIFSPNDKKSFC SIEGEWNGIMYAKYATGENTVFVDTKKLPIKKKKVRKLEDQNEYESRSLWK
DVT FNLKIRDIDAATEAKHRLEERQRAEARERKEKEIQWETRLFHEDGE CWVYDEPLLKRL
15 GAVKH

20

25

What is claimed is:

1. An isolated and/or purified polynucleotide molecule which hybridises at high stringency to an oligonucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which polynucleotide codes for a) a MAS receptor (i.e. a protein having ability to bind to 3 β -hydroxy-4,4-dimethylcholest-8,14,24-triene (herein designated FF-MAS)) or for a MAS signalling protein (i.e. a protein having ability to bind to FF-MAS); or b) a ligand binding domain of a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
2. The polynucleotide of the preceding claim, which is a RNA antisense sequence.
3. The polynucleotide of claim 1, which is a cDNA sequence.
4. The polynucleotide according to any one of the preceding claims, which encodes a polypeptide displaying MAS receptor (being able to bind to FF-MAS) or MAS signalling protein activity (being able to bind to FF-MAS).
5. The polynucleotide of claim 1, which encodes a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
6. The polynucleotide according to any one of the preceding claims having the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.
7. A probe of at least 12 nucleotides, said probe being capable of hybridising with nucleic acids which encode a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
8. A probe, according to the preceding claim, which comprises an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 capable of specifically hybridising with a gene which encodes a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), or allelic and species variants thereof.

9. The probe of the preceding claim, which comprises from about 40 to about 60 nucleotides in length.
- 5 10. The probe according to any one of the two preceding claims, which is labelled to provide a detectable signal.
11. The probe according to any one of the two preceding claims comprising the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.
- 10 12. A DNA construct comprising a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS); or b) a ligand binding domain
- 15 of a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
13. The DNA construct of the preceding claim, wherein the DNA sequence encodes a MAS receptor or MAS signalling protein having the amino acid sequence of SEQ ID NO: 2 or
- 20 SEQ ID NO: 4.
14. A cultured cell line, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID
- 25 NO: 3 and which encodes a) a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS); or b) a ligand binding domain or a transmembrane domain of a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 30 15. The cell line, yeast or bacteria according to the preceding claim, which does not express endogenous MAS receptor (being able to bind to FF-MAS) or MAS signalling proteins (being able to bind to FF-MAS).

16. An MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), a peptide fragment thereof or a salt thereof, which is isolated and/or purified.
- 5 17. The isolated and/or purified protein of the preceding claim, comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 or a sequence of said amino acid sequence being able to bind to FF-MAS.
- 10 18. An isolated antibody which specifically binds to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
19. The isolated antibody of the preceding claim wherein said antibody is a monoclonal antibody.
- 15 20. The isolated antibody according to any one of the preceding two claims, which blocks the binding of MAS to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 20 21. A hybridoma which produces a monoclonal antibody according to any of the two preceding claims.
- 25 22. A method for detecting the presence of a compound or a salt thereof which has affinity for a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), comprising the steps of a) contacting the compound with the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), a peptide fragment thereof or a salt thereof; and b) measuring the affinity of said compound for the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 30 23. The method of the preceding claim for detecting the presence of MAS antagonists, comprising the steps of a) exposing a compound in the presence of a MAS agonist including MAS to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor (being able to

bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) and an associated response through the pathway; and b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS),
5 relative to the stimulation of the response pathway by the MAS agonist alone and therefrom determining the presence of a MAS antagonist.

24. The method of any one of the two preceding claims for detecting the presence of MAS agonists, comprising the steps of a) exposing a compound in the presence of a MAS antagonist to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) and an associated response through the pathway; and b) detecting an increase of the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), relative to the stimulation of the response pathway by the MAS antagonist alone and therefrom determining the presence of a MAS agonist.

25. A compound or a salt thereof which has affinity for the MAS receptor (being able to bind to FF-MAS) or a MAS signalling peptide (being able to bind to FF-MAS) and which compound or salt is detected by the method according to claim 20 or 21.

26. A method for producing a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which comprises a) growing cells, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence of SEQ ID NO: 1 or SEQ ID NO: 3 coding for the expression of the MAS receptor or MAS signalling protein, and b) isolating the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) from the cells.

27. The method according to the preceding claim, wherein the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) is isolated by immunoaffinity purification.

28. A kit for screening a compound or a salt thereof which has affinity for a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), which contains the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), the peptide fragment thereof or a salt thereof.
29. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M.
30. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.
31. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M.
32. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.
33. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M.
34. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.

35. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M.
- 5 36. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.
- 10 37. A MAS receptor according to any one of the preceding claims to a MAS receptor, which is a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay.
38. A MAS receptor according to any one of the preceding claims to a MAS receptor, which is
15 a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.
39. A DNA construct which comprises a DNA sequence encoding a MAS receptor according
20 to any one of the preceding claims to a MAS receptor or a DNA sequence coding for a functional analog thereof (binding to FF-MAS).
40. A DNA construct which comprises a DNA sequence encoding a MAS receptor according
25 to any one of the preceding claims to a MAS receptor or a DNA sequence coding for a functional analog thereof (binding to FF-MAS), with the proviso that it is different from the nucleotides of SEQ ID NO: 5 and 7.
41. A DNA construct comprising the DNA sequence shown in SEQ ID NO: 1 or a fragment
30 thereof, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M.
42. A DNA construct according to the previous claim, which comprises the DNA sequence shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional

analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM , with the proviso that it is different from the nucleotides of SEQ ID NO: 5 and 7.

- 5 43. A DNA construct according to any one of the preceding claims on a DNA construct, which comprises the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM .
- 10 44. A DNA construct according to any one of the preceding claims on a DNA construct, which comprises the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM , with the proviso that it is different from the nucleotides of SEQ ID NO: 5 and 7.
- 15 45. A recombinant expression vector which carries an inserted DNA construct according to any one of the preceding claims to a DNA construct.
46. A cell containing a recombinant expression vector according to the preceding claim.
- 20 47. A cell containing a DNA construct according to any one of the preceding claims to a DNA construct integrated in its genome.
48. A cell according to any one of the two preceding claims, which is a eukaryotic cell, in particular an insect or a mammalian cell.
- 25 49. A method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-MAS activity, the method comprising incubating a MAS receptor according to any one of the preceding claims to a MAS receptor with a substance suspected to be an agonist or antagonist of FF-MAS, and subsequently with FF-MAS, or an analogue thereof, and detecting
- 30 any effect of binding of FF-MAS, or the analogue to the MAS receptor.
50. A method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-MAS activity, the method comprising incubating FF-MAS, or an analogue thereof with a substance suspected to be an agonist or antagonist of activity of FF-MAS, and subse-

quently with a MAS receptor according to any one of the preceding claims to a MAS receptor, and detecting any effect of binding of FF-MAS, or the analogue to the receptor.

51. Use of a MAS receptor according to any one of the preceding claims to a MAS receptor for
5 screening for agonists or antagonist of activity of FF-MAS.
52. Use of DNA constructs according to any one of the preceding claims to a NDA construct
for isolation of tissue and/or organ specific variants of the MAS receptor according to any
one of the preceding claim to a MAS receptor.
10
53. Use of a receptor isolated according to the preceding claim for the screening of MAS agonists or antagonist.

NOVO NORDISK A/S & SCHERING AKTIENGESELLSCHAFT

1/1




Figure 1: Displacement of ^3H -labelled FF-MAS from SAM1b

SEQUENCE LISTING

<110> NOVO NORDISK A/S

<120> SAM

<130> 6229.000-DK

<160> 4

10 <170> PatentIn version 3.0

<210> 1

<211> 2814

<212> DNA

15 <213> ARTIFICIAL SEQUENCE

<400> 1

	tttgtgtgtca ttggcggctc ccaagatggc gtccatcgtg gaagggccgc tgagcaaattg	60
20	gactaacgtg atgaagggat ggcagtatcg ttggttcgtg ctggactaca atgcagggct	120
	gctctcctac tacacgtcca aggacaaaat gatgagaggc tctcgaagag gatgcgttag	180
	actcagagga gctgtgattg gtatagacga cgaggacgac agcaccttca caatcactgt	240
25	cgatcagaaa accttcact tccaggtctg agatgcagac gagcgagaga agtggatcca	300
	tgccttagaa gaaactattc ttgccatac tcttcagctt caagggttgg attcaggatt	360
30	catccccagt gtccaagact ttgataagaa acttaccgag gctgacgcgt acctgcagat	420
	cttgatagaa caattaaagc tttttgatga caagcttcaa aattgtaaag atgatgaaca	480
	gagaaagaaa gttgaaactc tcaaagacac aacaaatagc atggtagaat caattaaaca	540
35	ctgcattgtg ttgctacaga ttgctaaaag tactattaat cctgtagatg caatatacca	600
	gcctagtccc ttggaacctg tgatcagcac aatgccttcc cagactgcct tacctccaga	660
40	acccgctcag ttgtgtaagt cagagcagcg tccatcttcc ttacctgttg gacctgtgtt	720
	agctaccttg ggacatcatc agactccaac accaaatagt acaggcagtg ggaactcacc	780
	acctagcagc agtctgactc ctcccagcca tgtcaacttg tctccaaata cagtccaga	840
45	gttctcttac tctagcagtg aagatgagtt ctatgatgct gatgaattcc atcaaagtgg	900
	ctcgtcccca aagcgcttaa tagattcttc tggatctgcc tcagtcttga cacacagcag	960
50	ctccggaaat agcttaaaac gccagatac cacagagtct ctgaattcct ccatgtccaa	1020
	tggcacaagc gatgctgac tttttgactc acatgacgac agagatgatg atggggaggg	1080
	tgggtcagtg gaggagcaca agagcgttat catgcacctc ttatcacaag tcaggctggg	1140
55	gatggacctc acaaaggtag ttcttccaac gtttattctc gagagaagat ctctgttaga	1200
	aatgtatgca gactttttcg cacatccaga cctgttcgtg agcattagtg atcagaagga	1260
60	tcccagggat cgaatggttc aggttgtgaa atggtacctc tcggccttcc atgcaggaag	1320

	gagaggatcg gtggccaaaa agcogtaciaa tcctatittg ggtgagatct ttcagtgtca	1380
	ctggacgttg ccgaatgata ctgaagagaa cgcagagctc gtttcagaag ggccggttcc	1440
5	ctgggtttct aagaacagtg taacatttgt ggctgagcaa gtttcccacc atccgcccatt	1500
	ttcagccttt tatgctgagt gttttaacaa gaagatacaa ttcaatgctc atatctggac	1560
10	taaatcaaaa ttccttggga tgtcaattgg ggtacacaa ataggtcagg gctgtgtctc	1620
	gtgtctggag tacgatgagc actacatcct caggttcccc aatggctatg gaaggtctat	1680
	cctgacagtg ccctgggtgg aattgggagg agaattgcaat atcaactgct ccaaaacggg	1740
15	ttacagcgca aacatogtct tccacactaa gcctttctat gggggcaaga agcacagaat	1800
	tactgcagag attttttctc cgaatgacaa gaaatccttc tgctcaattg aaggggaatg	1860
20	gaatggtatc atgtatgcaa aatacgcaac aggggaaaac actgtctttg tagacaccaa	1920
	gaaattgcct ataataaga aaaagggtgag gaagttggaa gatcagaatg agtatgagtc	1980
	ccgcagcctt tggaaggatg tcactttcaa tttaaaaatc agagacattg atgcagcaac	2040
25	ggaagcaaag cacagacttg aagaaagaca aagagcagaa gcccagagaa ggaaggagaa	2100
	ggaaattcag tgggagacga ggctctttca cgaggatggc gaatgctggg tttacgatga	2160
30	gcctttactg aagcgtcttg gtgctgtgaa gcattaggcc gacaaccgag tccacacctg	2220
	gtgaccaggg cagtaggcgt aattaagcaa caatcgatct tccttcagga gagcttgtca	2280
	cttccttctt aacgcagtgg ttcctatctc agggatactg gacttgacga cacagatgaa	2340
35	caattaaagt ggaaaccgct tcccttttct cctctgtggc agttacaatt ttgacttcag	2400
	gcctgagaaa aacttcaggt ttcgaaacat gacatctctt ccttttccag atcccatgct	2460
40	ttgaaaaata tttatagaca gttccaggtc tcagcttcct gtctcttagt tctgctgttc	2520
	gggcataaaa tctttatctc cagttcatat aatcttgagt tttagataka cacacatgag	2580
	taacagctga cagtttttca caagtacacc cacctgtaaa tactgtakcc tcagtttaga	2640
45	aaattagtgc atgtatgaaa atcaagtgtt aggaaatttc atggtttcac ctataacctt	2700
	tatttttagaa ttgaactatg attagattgt atctaaacct gaagtataat tatatgcagt	2760
50	gcttcttaag gcttcataaa ataattttcc aaccttttta aaaaaaaaaa aaaa	2814

<210> 2
 <211> 723
 <212> PRT
 5 <213> ARTIFICIAL SEQUENCE
 <400> 2

10 Met Ala Ser Ile Val Glu Gly Pro Leu Ser Lys Trp Thr Asn Val Met
 1 5 10 15
 Lys Gly Trp Gln Tyr Arg Trp Phe Val Leu Asp Tyr Asn Ala Gly Leu
 20 25 30
 15 Leu Ser Tyr Tyr Thr Ser Lys Asp Lys Met Met Arg Gly Ser Arg Arg
 35 40 45
 Gly Cys Val Arg Leu Arg Gly Ala Val Ile Gly Ile Asp Asp Glu Asp
 50 55 60
 20 Asp Ser Thr Phe Thr Ile Thr Val Asp Gln Lys Thr Phe His Phe Gln
 65 70 75 80
 Ala Arg Asp Ala Asp Glu Arg Glu Lys Trp Ile His Ala Leu Glu Glu
 25 85 90 95
 Thr Ile Leu Arg His Thr Leu Gln Leu Gln Gly Leu Asp Ser Gly Phe
 100 105 110
 30 Ile Pro Ser Val Gln Asp Phe Asp Lys Lys Leu Thr Glu Ala Asp Ala
 115 120 125
 Tyr Leu Gln Ile Leu Ile Glu Gln Leu Lys Leu Phe Asp Asp Lys Leu
 130 135 140
 35 Gln Asn Cys Lys Asp Asp Glu Gln Arg Lys Lys Val Glu Thr Leu Lys
 145 150 155 160
 Asp Thr Thr Asn Ser Met Val Glu Ser Ile Lys His Cys Ile Val Leu
 40 165 170 175
 Leu Gln Ile Ala Lys Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln
 180 185 190
 45 Pro Ser Pro Leu Glu Pro Val Ile Ser Thr Met Pro Ser Gln Thr Ala
 195 200 205
 Leu Pro Pro Glu Pro Ala Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser
 210 215 220
 50 Ser Leu Pro Val Gly Pro Val Leu Ala Thr Leu Gly His His Gln Thr
 225 230 235 240
 Pro Thr Pro Asn Ser Thr Gly Ser Gly Asn Ser Pro Pro Ser Ser Ser
 245 250 255
 55 Leu Thr Pro Pro Ser His Val Asn Leu Ser Pro Asn Thr Val Pro Glu
 260 265 270
 60 Phe Ser Tyr Ser Ser Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe
 275 280 285

His Gln Ser Gly Ser Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser
 290 295 300

5 Ala Ser Val Leu Thr His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro
 305 310 315 320

Asp Thr Thr Glu Ser Leu Asn Ser Ser Met Ser Asn Gly Thr Ser Asp
 325 330 335

10 Ala Asp Leu Phe Asp Ser His Asp Asp Arg Asp Asp Asp Gly Glu Ala
 340 345 350

Gly Ser Val Glu Glu His Lys Ser Val Ile Met His Leu Leu Ser Gln
 355 360 365

15 Val Arg Leu Gly Met Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile
 370 375 380

20 Leu Glu Arg Arg Ser Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His
 385 390 395 400

Pro Asp Leu Phe Val Ser Ile Ser Asp Gln Lys Asp Pro Arg Asp Arg
 405 410 415

25 Met Val Gln Val Val Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg
 420 425 430

Arg Gly Ser Val Ala Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile
 435 440 445

30 Phe Gln Cys His Trp Thr Leu Pro Asn Asp Thr Glu Glu Asn Ala Glu
 450 455 460

35 Leu Val Ser Glu Gly Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr
 465 470 475 480

Phe Val Ala Glu Gln Val Ser His His Pro Pro Ile Ser Ala Phe Tyr
 485 490 495

40 Ala Glu Cys Phe Asn Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr
 500 505 510

Lys Ser Lys Phe Leu Gly Met Ser Ile Gly Val His Asn Ile Gly Gln
 515 520 525

45 Gly Cys Val Ser Cys Leu Glu Tyr Asp Glu His Tyr Ile Leu Thr Phe
 530 535 540

50 Pro Asn Gly Tyr Gly Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu
 545 550 555 560

Gly Gly Glu Cys Asn Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn
 565 570 575

55 Ile Val Phe His Thr Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile
 580 585 590

Thr Ala Glu Ile Phe Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile
 595 600 605

60 Glu Gly Glu Trp Asn Gly Ile Met Tyr Ala Lys Tyr Ala Thr Gly Glu
 610 615 620

	Asn	Thr	Val	Phe	Val	Asp	Thr	Lys	Lys	Leu	Pro	Ile	Ile	Lys	Lys	Lys	
	625					630					635					640	
5	Val	Arg	Lys	Leu	Glu	Asp	Gln	Asn	Glu	Tyr	Glu	Ser	Arg	Ser	Leu	Trp	
				645						650					655		
	Lys	Asp	Val	Thr	Phe	Asn	Leu	Lys	Ile	Arg	Asp	Ile	Asp	Ala	Ala	Thr	
				660					665					670			
10	Glu	Ala	Lys	His	Arg	Leu	Glu	Glu	Arg	Gln	Arg	Ala	Glu	Ala	Arg	Glu	
			675					680					685				
	Arg	Lys	Glu	Lys	Glu	Ile	Gln	Trp	Glu	Thr	Arg	Leu	Phe	His	Glu	Asp	
15		690					695					700					
	Gly	Glu	Cys	Trp	Val	Tyr	Asp	Glu	Pro	Leu	Leu	Lys	Arg	Leu	Gly	Ala	
	705					710					715					720	
20	Val	Lys	His														

<210> 3
 <211> 2534
 <212> DNA
 <213> ARTIFICIAL SEQUENCE

5
 <400> 3
 gggcccccctcc cctgagacgg cggccggccg ccgcgaatgg ctctcctgct ggccgcttgc 60
 ggagggttttg attcaggatt catccccagt gtccaagact ttgataagaa acttaccgag 120
 10 gctgacgcgt acctgcagat cttgatagaa caattaaagc tttttgatga caagcttcaa 180
 aattgtaaag atgatgaaca gagaaagaaa gttgaaactc tcaaagacac aacaaatagc 240
 15 atggtagaat caattaaaca ctgcattgtg ttgctacaga ttgctaaaag tactattaat 300
 cctgtagatg caatatacca gcctagtccc ttggaacctg tgatcagcac aatgccttcc 360
 cagactgcct tacctccaga acccgctcag ttgtgtaagt cagagcagcg tccatcttcc 420
 20 ttacctgttg gacctgtgtt agctaccttg ggacatcatc agactccaac accaaatagt 480
 acaggcagtg ggaactcacc acctagcagc agtctgactc ctcccagcca tgtcaacttg 540
 25 tctccaaata cagtcccaga gttctcttac tctagcagtg aagatgagtt ctatgatgct 600
 gatgaattcc atcaaagtgg ctcgccccca aagcgcttaa tagattcttc tggatctgcc 660
 tcagtcttgā cacacagcag ctccggaaat agcttaaaac gccagatac cacagagtct 720
 30 ctgaattcct ccatgtccaa tggcacaagc gatgctgac tttttgactc acatgacgac 780
 agagatgatg atggggaggc tgggtcagtg gaggagcaca agagcgttat catgcacctc 840
 35 ttatcacaag tcaggctggg gatggacctc acaaaggtag ttcttccaac gtttattctc 900
 gagagaagat ctctgttaga aatgtatgca gactttttcg cacatccaga cctgttcgtg 960
 agcattagtg atcagaagga tcccagggat cgaatggttc aggttggtgaa atggtacctc 1020
 40 tcggccttcc atgcaggaag gagaggatcg gtggccaaaa agccgtacaa tcctattttg 1080
 ggtgagatct ttcagtgtca ctggacgttg ccgaatgata ctgaagagaa cgcagagctc 1140
 45 gtttcagaag ggccggttcc ctgggtttct aagaacagtg taacatttgt ggctgagcaa 1200
 gtttcccacc atccgcccat ttcagccttt tatgctgagt gttttaacaa gaagatacaa 1260
 ttcaatgctc atatctggac taaatcaaaa ttccttgga tgtcaattgg ggtacacaac 1320
 50 ataggtcagg gctgtgtctc gtgtctggag tacgatgagc actacatcct cacgttcccc 1380
 aatggctatg gaaggctctat cctgacagtg ccctgggttg aattgggagg agaatgcaat 1440
 55 atcaactgct ccaaaacggg ttacagcgca aacatcgtct tccacactaa gcctttctat 1500
 gggggcaaga agcacagaat tactgcagag attttttctc cgaatgacaa gaaatccttc 1560
 tgetcaattg aaggggaaatg gaatggtatc atgtatgcaa aatacgcaac aggggaaaac 1620
 60 actgtctttg tagacaccaa gaaattgcct ataatacaaga aaaagggtgag gaagttggaa 1680

	gatcagaatg agtatgagtc ccgcagcctt tggaaggatg tcactttcaa tttaaaaatc	1740
	agagacattg atgcagcaac ggaagcaaag cacagacttg aagaaagaca aagagcagaa	1800
5	gcccagaaaa ggaaggagaa ggaaattcag tgggagacga ggctctttca cgaggatggc	1860
	gaatgctggg tttacgatga gcctttactg aagcgtcttg gtgctgtgaa gcattaggcc	1920
	gacaaccgag tccacacctg gtgaccaggg cagtaggcgt aattaagcaa caatcgatct	1980
10	tccttcagga gagcttgtca cttccttctt aacgcagtgg ttcttatctc agggatactg	2040
	gacttgacga cacagatgaa caattaaagt ggaaaccgct tcccttttct cctctgtggc	2100
15	agttacaatt ttgacttcag gcctgagaaa aacttcaggt ttcgaaacat gacatctctt	2160
	ccttttccag atcccatgct ttgaaaaata tttatagaca gttccaggtc tcagcttcct	2220
	gtcctctagt tctgctgttc gggcataaaa tctttatctc cagttcatat aatcttgagt	2280
20	tttagataka cacacatgcg taacagctga cagtttttca caagtacacc cacctgtaaa	2340
	tactgtakcc tcagtttaga aaattagtgc atgtatgaaa atcaagtgtt aggaaatttc	2400
25	atggtttcac ctataacctt tatttttagaa ttgaactatg attagattgt atctaaacct	2460
	gaagtataat tatatgcagt gcttcttaag gcttcataaa ataattttcc aaccttttta	2520
30	aaaaaaaaaa aaaa	2534

<210> 4
 <211> 626
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

5

<400> 4

Met Ala Leu Leu Leu Ala Ala Cys Gly Gly Leu Asp Ser Gly Phe Ile
 1 5 10 15
 Pro Ser Val Gln Asp Phe Asp Lys Lys Leu Thr Glu Ala Asp Ala Tyr
 20 25 30
 Leu Gln Ile Leu Ile Glu Gln Leu Lys Leu Phe Asp Asp Lys Leu Gln
 35 40 45
 Asn Cys Lys Asp Asp Glu Gln Arg Lys Lys Val Glu Thr Leu Lys Asp
 50 55 60
 Thr Thr Asn Ser Met Val Glu Ser Ile Lys His Cys Ile Val Leu Leu
 65 70 75 80
 Gln Ile Ala Lys Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln Pro
 85 90 95
 Ser Pro Leu Glu Pro Val Ile Ser Thr Met Pro Ser Gln Thr Ala Leu
 100 105 110
 Pro Pro Glu Pro Ala Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser Ser
 115 120 125
 Leu Pro Val Gly Pro Val Leu Ala Thr Leu Gly His His Gln Thr Pro
 130 135 140
 Thr Pro Asn Ser Thr Gly Ser Gly Asn Ser Pro Pro Ser Ser Ser Leu
 145 150 155 160
 Thr Pro Pro Ser His Val Asn Leu Ser Pro Asn Thr Val Pro Glu Phe
 165 170 175
 Ser Tyr Ser Ser Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe His
 180 185 190
 Gln Ser Gly Ser Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser Ala
 195 200 205
 Ser Val Leu Thr His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro Asp
 210 215 220
 Thr Thr Glu Ser Leu Asn Ser Ser Met Ser Asn Gly Thr Ser Asp Ala
 225 230 235 240
 Asp Leu Phe Asp Ser His Asp Asp Arg Asp Asp Asp Gly Glu Ala Gly
 245 250 255
 Ser Val Glu Glu His Lys Ser Val Ile Met His Leu Leu Ser Gln Val
 260 265 270
 Arg Leu Gly Met Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile Leu
 275 280 285
 Glu Arg Arg Ser Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His Pro

	290	295	300		
	Asp Leu Phe Val Ser Ile Ser Asp Gln Lys Asp Pro Arg Asp Arg Met				
	305	310	315	320	
5	Val Gln Val Val Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg Arg				
		325	330	335	
10	Gly Ser Val Ala Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile Phe				
		340	345	350	
	Gln Cys His Trp Thr Leu Pro Asn Asp Thr Glu Glu Asn Ala Glu Leu				
		355	360	365	
15	Val Ser Glu Gly Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr Phe				
		370	375	380	
	Val Ala Glu Gln Val Ser His His Pro Pro Ile Ser Ala Phe Tyr Ala				
		385	390	395	400
20	Glu Cys Phe Asn Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr Lys				
		405	410	415	
25	Ser Lys Phe Leu Gly Met Ser Ile Gly Val His Asn Ile Gly Gln Gly				
		420	425	430	
	Cys Val Ser Cys Leu Glu Tyr Asp Glu His Tyr Ile Leu Thr Phe Pro				
		435	440	445	
30	Asn Gly Tyr Gly Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu Gly				
		450	455	460	
	Gly Glu Cys Asn Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn Ile				
		465	470	475	480
35	Val Phe His Thr Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile Thr				
		485	490	495	
40	Ala Glu Ile Phe Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile Glu				
		500	505	510	
	Gly Glu Trp Asn Gly Ile Met Tyr Ala Lys Tyr Ala Thr Gly Glu Asn				
		515	520	525	
45	Thr Val Phe Val Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Lys Val				
		530	535	540	
	Arg Lys Leu Glu Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp Lys				
		545	550	555	560
50	Asp Val Thr Phe Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr Glu				
		565	570	575	
	Ala Lys His Arg Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu Arg				
		580	585	590	
55	Lys Glu Lys Glu Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp Gly				
		595	600	605	
60	Glu Cys Trp Val Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala Val				
		610	615	620	

Lys His
625

5	<210>	5																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		</
---	-------	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

gatgtcaatt ggggtgcaca acatagggca gggctgtgtc tcatgtctag actatgatga 1620
 5 acattacatt ctcacattcc ccaatggcta tggaaggtct atcctcacag tgccctgggt 1680
 ggaattagga ggagaatgca atattaattg ttccaaaaca ggctatagtg caaatatcat 1740
 cttccacact aaacccttct atgggggcaa gaagcacaga attactgccg agattttttc 1800
 10 tccaaatgac aagaagtctt tttgctcaat tgaaggggaa tggaatggtg tgatgtatgc 1860
 aaaatatgca acaggggaaa atacagtctt tgtagatacc aagaagttgc ctataatcaa 1920
 15 gaagaaagtg aggaagttgg aagatcagaa cgagtatgaa tcccgagcc tttggaagga 1980
 tgtcactttc aacttaaaaa tcagagacat tgatgcagca actgaagcaa agcacaggct 2040
 tgaagaaaga caaagagcag aagcccaga aaggaaggag aaggaaattc agtgggagac 2100
 20 aaggttattt catgaagatg gagaatgetg ggtttatgat gaaccattac tgaaacgtct 2160
 tgggtgtgcc aagcattagg ttggaagatg caaagtttat acctgatgat cagggcagta 2220
 25 ggcataattc agcaacaaac aatcttcctt tgggagaaac ctgttcattc caatcttcta 2280
 attacagtgg ttcctatctc agggatactg gactttctga cgcagatgaa caattaaggg 2340
 gaaaagcttc ccttttccct ctgtggcagt tacgattttg acttcagtcc tgagaaaaac 2400
 30 ttcaggtttt gaaaatcaga tgatgtcttc tccttttcca aacaccacac gttgaaagca 2460
 tttataaatc caagtctgaa actctgcgct ctagtactgc tgttaagata cacaacttgt 2520
 35 ttcttagttc atataatctc gggatacaca cacacacaca tatatatata cacacacata 2580
 cgtatacaca cacatacata tataaatata cctgatgcc aatttttttc ataaatattc 2640
 tgcctactgt aaatatgggt tcctctgagt tgttttagaa aattagcgca atgtattaaa 2700
 40 atcaagtgtt aggaaatttc atggtcttac ctacaataac ttttattttg gaattgaact 2760
 attattaaat tgtatcta atcctggattac agtttaatta attattctta gtgcttaagg 2820
 45 cttcataaag taatttttcc 2840

<210> 6
 <211> 723
 <212> PRT
 50 <213> Homo sapiens
 <400> 6

55 Met Ala Ser Ile Met Glu Gly Pro Leu Ser Lys Trp Thr Asn Val Met
 1 5 10 15
 60 Lys Gly Trp Gln Tyr Arg Trp Phe Val Leu Asp Tyr Asn Ala Gly Leu
 20 25 30

12

Leu Ser Tyr Tyr Thr Ser Lys Asp Lys Met Met Arg Gly Ser Arg Arg
 35 40 45

5 Gly Cys Val Arg Leu Arg Gly Ala Val Ile Gly Ile Asp Asp Glu Asp
 50 55 60

10 Asp Ser Thr Phe Thr Ile Thr Val Asp Gln Lys Thr Phe His Phe Gln
 65 70 75 80

15 Ala Arg Asp Ala Asp Glu Arg Glu Lys Trp Ile His Ala Leu Glu Glu
 85 90 95

20 Thr Ile Leu Arg His Thr Leu Gln Leu Gln Gly Leu Asp Ser Gly Phe
 100 105 110

25 Val Pro Ser Val Gln Asp Phe Asp Lys Lys Leu Thr Glu Ala Asp Ala
 115 120 125

30 Tyr Leu Gln Ile Leu Ile Glu Gln Leu Lys Leu Phe Asp Asp Lys Leu
 130 135 140

35 Gln Asn Cys Lys Glu Asp Glu Gln Arg Lys Lys Ile Glu Thr Leu Lys
 145 150 155 160

40 Glu Thr Thr Asn Ser Met Val Glu Ser Ile Lys His Cys Ile Val Leu
 165 170 175

45 Leu Gln Ile Ala Lys Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln
 180 185 190

50 Pro Ser Pro Leu Glu Pro Val Ile Ser Thr Met Pro Ser Gln Thr Val
 195 200 205

55 Leu Pro Pro Glu Pro Val Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser
 210 215 220

60 Ser Leu Pro Val Gly Pro Val Leu Ala Thr Leu Gly His His Gln Thr
 225 230 235 240

65 Pro Thr Pro Asn Ser Thr Gly Ser Gly His Ser Pro Pro Ser Ser Ser
 245 250 255

70 Leu Thr Ser Pro Ser His Val Asn Leu Ser Pro Asn Thr Val Pro Glu
 260 265 270

75 Phe Ser Tyr Ser Ser Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe
 275 280 285

5 His Gln Ser Gly Ser Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser
 290 295 300
 Ala Ser Val Leu Thr His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro
 305 310 315 320
 10 Asp Thr Thr Glu Ser Leu Asn Ser Ser Leu Ser Asn Gly Thr Ser Asp
 325 330 335
 15 Ala Asp Leu Phe Asp Ser His Asp Asp Arg Asp Asp Ala Glu Ala
 340 345 350
 20 Gly Ser Val Glu Glu His Lys Ser Val Ile Met His Leu Leu Ser Gln
 355 360 365
 25 Val Arg Leu Gly Met Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile
 370 375 380
 Leu Glu Arg Arg Ser Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His
 385 390 395 400
 30 Pro Asp Leu Phe Val Ser Ile Ser Asp Gln Lys Asp Pro Lys Asp Arg
 405 410 415
 35 Met Val Gln Val Val Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg
 420 425 430
 40 Lys Gly Ser Val Ala Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile
 435 440 445
 45 Phe Gln Cys His Trp Thr Leu Pro Asn Asp Thr Glu Glu Asn Thr Glu
 450 455 460
 Leu Val Ser Glu Gly Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr
 465 470 475 480
 50 Phe Val Ala Glu Gln Val Ser His His Pro Pro Ile Ser Ala Phe Tyr
 485 490 495
 55 Ala Glu Cys Phe Asn Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr
 500 505 510
 60 Lys Ser Lys Phe Leu Gly Met Ser Ile Gly Val His Asn Ile Gly Gln
 515 520 525

14

Gly Cys Val Ser Cys Leu Asp Tyr Asp Glu His Tyr Ile Leu Thr Phe
 530 535 540

5 Pro Asn Gly Tyr Gly Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu
 545 550 555 560

10 Gly Gly Glu Cys Asn Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn
 565 570 575

15 Ile Ile Phe His Thr Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile
 580 585 590

Thr Ala Glu Ile Phe Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile
 595 600 605

20 Glu Gly Glu Trp Asn Gly Val Met Tyr Ala Lys Tyr Ala Thr Gly Glu
 610 615 620

25 Asn Thr Val Phe Val Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Lys
 625 630 635 640

30 Val Arg Lys Leu Glu Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp
 645 650 655

35 Lys Asp Val Thr Phe Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr
 660 665 670

Glu Ala Lys His Arg Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu
 675 680 685

40 Arg Lys Glu Lys Glu Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp
 690 695 700

45 Gly Glu Cys Trp Val Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala
 705 710 715 720

50 Ala Lys His

55 <210> 7
 <211> 2457
 <212> DNA
 <213> Homo sapiens

<400> 7

60 cggcccctac ccctgagtcc ccgggggtccc ggccgccagg ccggagcgcg aatgtcgtgc 60
 tcaccctgcc tccttcccgc cgccccctgg gctttttgat gacaagcttc aaaactgcaa 120

	agaagatgaa cagagaaaga aaattgaaac tctcaaagag acaacaaata gcatggtaga	180
5	atcaattaaa cactgcattg tgttgctgca gattgccaaa agtactatta atcccgtaga	240
	tgcaatatat caacctagtc ctttggaaacc tgtgatcagc acaatgcctt cccagactgt	300
	gttacctcca gaacctgttc agttgtgtaa gtcagagcag cgtccatctt ccctaccagt	360
10	tggacctgtg ttggctacct tgggacatca tcagactcct acaccaaata gtacaggcag	420
	tggccattca ccaccgagta gcagtctcac ttctccaagc cacgtgaact tgtctccaaa	480
15	tacagtccca gagttctctt actocagcag tgaagatgaa ttttatgatg ctgatgaatt	540
	ccatcaaagt ggctcatccc caaagcgctt aatagattct tctggatctg cctcagtcct	600
	gacacacagc agctcgggaa atagtctaaa acgccagat accacagaat cacttaattc	660
20	ttccttgtcc aatggaacaa gtgatgctga cctgtttgat tcacatgatg acagagatga	720
	tgatgcggag gcagggtctg tggaggagca caagagcgtt atcatgcac tcttgtcgca	780
25	ggtagactt ggaatggatc ttactaaggt agttcttcca acgtttattc ttgaaagaag	840
	atctcttitta gaaatgtatg cagacttttt tgcacatccg gacctgtttg tgagcattag	900
	tgaccagaag gatcccaagg atcgaatggg tcaggttggt aaatggtacc tctcagcctt	960
30	tcatgcggga aggaaaggat cagttgccaa aaagccatac aatcccattt tgggcgagat	1020
	ttttcagtgt cattggacat taccaaatga tactgaagag aacacagaac tagtttcaga	1080
35	aggaccagtt ccctgggttt ccaaaaacag tgtaacattt gtggctgagc aggtttccca	1140
	tcatccaccc atttcagcct tttatgctga gtgttttaac aagaagatac aattcaatgc	1200
	tcatatctgg accaaatcaa aattccttgg gatgtcaatt ggggtgcaca acatagggca	1260
40	gggctgtgtc tcatgtctag actatgatga acattacatt ctacattcc ccaatggcta	1320
	tggaaggctc atcctcacag tgccctgggt ggaattagga ggagaatgca atattaattg	1380
45	ttccaaaaca ggctacagtg caaatatcat ctccacact aaacccttct atgggggcaa	1440
	gaagcacaga attactgccg agattttttc tccaaatgac aagaagtctt tttgttcaat	1500
	tgaaggggaa tggaatggtg tgatgtatgc aaaatatgca acaggggaaa atacagtctt	1560
50	tgtagatacc aagaagttgc ctataatcaa gaagaaagtg aggaagttgg aagatcagaa	1620
	cgagtatgaa tcccgcagcc tttggaagga tgtcactttc aacttaaaaa tcagagacat	1680
55	tgatgcagca actgaagcaa agcacaggct tgaagaaaga caaagagcag aagcccgaga	1740
	aaggaaggag aaggaaattc agtgggagac aaggttattt catgaagatg gagaatgctg	1800
	ggtttatgat gaaccattac tgaaacgtct tgggtgtgcc aagcattagg ttggaagatg	1860
60	caaagtttat acctgatgat cagggcagta ggcataattc agcaacaaac aatcttcctt	1920
	tgggagaac ctgttcattc caatcttcta attacagtgg ttctatctc agggatactg	1980

gactttctga cgcagatgaa caattaaggg gaaaagcttc ctttttcct ctgtggcagt 2040
 5 tacgattttg acttcagtcc tgagaaaaac ttcaggtttt gaaatcaga tgatgtcttc 2100
 tccttttcca aacaccacac gttgaaagca ttataaatc caagtctgaa actctgogct 2160
 ctagtactgc tgtaagata cacaacttgt ttcttagttc atataatctc gggatacaca 2220
 10 cacacacaca catatatata cacacacata cgtatacaca cacatacata tatataaata 2280
 tacctgatgc cagatTTTTT tcataaatat tctgcctact gtaaatatgg gttcctctga 2340
 gttgttttag aaaattagcg caatgtatta aaatcaagtg ttaggaaatt tcatggctctt 2400
 15 acctacaata acttttattt tggaattgaa ctattattaa attgtatcta atcctgg 2457

<210> 8
 20 <211> 558
 <212> PRT
 <213> Homo sapiens

<400> 8

25 Met Val Glu Ser Ile Lys His Cys Ile Val Leu Leu Gln Ile Ala Lys
 1 5 10 15

30 Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln Pro Ser Pro Leu Glu
 20 25 30

35 Pro Val Ile Ser Thr Met Pro Ser Gln Thr Val Leu Pro Pro Glu Pro
 35 40 45

40 Val Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser Ser Leu Pro Val Gly
 50 55 60

45 Pro Val Leu Ala Thr Leu Gly His His Gln Thr Pro Thr Pro Asn Ser
 65 70 75 80

50 Thr Gly Ser Gly His Ser Pro Pro Ser Ser Ser Leu Thr Ser Pro Ser
 85 90 95

55 His Val Asn Leu Ser Pro Asn Thr Val Pro Glu Phe Ser Tyr Ser Ser
 100 105 110

60 Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe His Gln Ser Gly Ser
 115 120 125

60 Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser Ala Ser Val Leu Thr
 130 135 140

His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro Asp Thr Thr Glu Ser
 145 150 155 160

5 Leu Asn Ser Ser Leu Ser Asn Gly Thr Ser Asp Ala Asp Leu Phe Asp
 165 170 175

10 Ser His Asp Asp Arg Asp Asp Asp Ala Glu Ala Gly Ser Val Glu Glu
 180 185 190

15 His Lys Ser Val Ile Met His Leu Leu Ser Gln Val Arg Leu Gly Met
 195 200 205

20 Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile Leu Glu Arg Arg Ser
 210 215 220

25 Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His Pro Asp Leu Phe Val
 225 230 235 240

30 Ser Ile Ser Asp Gln Lys Asp Pro Lys Asp Arg Met Val Gln Val Val
 245 250 255

35 Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg Lys Gly Ser Val Ala
 260 265 270

40 Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile Phe Gln Cys His Trp
 275 280 285

45 Thr Leu Pro Asn Asp Thr Glu Glu Asn Thr Glu Leu Val Ser Glu Gly
 290 295 300

50 Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr Phe Val Ala Glu Gln
 305 310 315 320

55 Val Ser His His Pro Pro Ile Ser Ala Phe Tyr Ala Glu Cys Phe Asn
 325 330 335

60 Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr Lys Ser Lys Phe Leu
 340 345 350

Gly Met Ser Ile Gly Val His Asn Ile Gly Gln Gly Cys Val Ser Cys
 355 360 365

Leu Asp Tyr Asp Glu His Tyr Ile Leu Thr Phe Pro Asn Gly Tyr Gly
 370 375 380

Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu Gly Gly Glu Cys Asn

18

	385		390		395		400
5	Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn Ile Ile Phe His Thr	405		410		415	
10	Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile Thr Ala Glu Ile Phe	420		425		430	
15	Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile Glu Gly Glu Trp Asn	435		440		445	
	Gly Val Met Tyr Ala Lys Tyr Ala Thr Gly Glu Asn Thr Val Phe Val	450		455		460	
20	Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Lys Val Arg Lys Leu Glu	465		470		475	480
25	Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp Lys Asp Val Thr Phe	485		490		495	
30	Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr Glu Ala Lys His Arg	500		505		510	
	Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu Arg Lys Glu Lys Glu	515		520		525	
35	Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp Gly Glu Cys Trp Val	530		535		540	
40	Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala Ala Lys His	545		550		555	
45	<210> 9						
	<211> 21						
	<212> DNA						
	<213> Artificial						
50	<400> 9						
	ccaagctcta atacgactca c						21
55	<210> 10						
	<211> 20						
	<212> DNA						
	<213> Artificial						
60	<400> 10						
	ctcagccaca aatgttacac						20

<210> 11
 <211> 32
 <212> DNA
 <213> Artificial
 5 <400> 11
 ctagctagca ccatggcgctc catcgtggaa gg 32

10 <210> 12
 <211> 35
 <212> DNA
 <213> Artificial

15 <400> 12
 ataagaatgc ggccgcgagg agaaaaggga agcgg 35

20 <210> 13
 <211> 35
 <212> DNA
 <213> Artificial

25 <400> 13
 ctagctagca ccatggctct cctgctggcc gcttg 35

30 <210> 14
 <211> 29
 <212> DNA
 <213> Artificial

35 <400> 14
 cccgggcatg cttcacagca ccaagacgc 29